NCT04443751
A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) No drug interventions treatment 1 completed NCT03680677
Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies No drug interventions Not Available Not Available recruiting NCT02053545
Haplo-identical SCT for High Risk (HR) Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion No drug interventions treatment 1 / 2 withdrawn NCT01497145
A Clinical Study of KRN321 in Adult Subjects With Myelodysplastic Syndrome No drug interventions treatment 2 completed NCT04857645
ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients No drug interventions treatment 2 active_not_recruiting NCT05025098
Precision Therapy Versus Standard Therapy in AML and MDS in Elderly treatment 2 recruiting NCT06267898
Non Interventional Study on Iron Toxicity After First Allo-transplant in MDS/CMML No drug interventions Not Available Not Available completed NCT00814983
Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft No drug interventions treatment 1 / 2 terminated NCT00321711
Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents supportive_care 2 completed NCT04473911
Haplo Peripheral Blood Sct In GVHD Prevention treatment 1 active_not_recruiting NCT04358393
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS treatment 1 / 2 recruiting NCT02103478
Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS) treatment 1 / 2 completed NCT02214407
Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML treatment 3 completed NCT04638309
APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS) treatment 1 terminated NCT00636909
Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders treatment 2 completed NCT05009537
Optical Genome Mapping in Hematological Malignancies No drug interventions Not Available Not Available recruiting NCT03336632
Chidamide Plus PTCy/Cyclosporine to Prevent GVHD After Myeloablative Conditioning, Matched PBSCT treatment 2 unknown_status NCT03459859
Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS treatment 1 completed NCT05583175
Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies treatment 2 recruiting NCT05476770
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies treatment 1 recruiting NCT02161042
The Effect of Blood Transfusion on Endothelial Function No drug interventions Not Available Not Available completed NCT05184842
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML treatment 2 recruiting NCT00699842
A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients treatment 1 / 2 terminated NCT00309842
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases treatment 2 completed NCT04645199
National Longitudinal Cohort of Hematological Diseases No drug interventions Not Available Not Available recruiting NCT01861106
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations treatment 2 recruiting NCT04806906
Pilot Study of CC 486 (Oral Azacitidine) Plus BSC as Maintenance After sc Azacitidine in Elderly HR-IPSS-R MDS Patients treatment 2 active_not_recruiting NCT05285813
A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure treatment 2 recruiting NCT05687513
Clinical Efficacy and Mechanism of Yisui Granule in Treatment of Low and Medium Risk Myelodysplastic Syndrome Through Demethylation No drug interventions treatment 0 not_yet_recruiting NCT00530218
Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant supportive_care 2 completed NCT01993641
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA treatment 2 completed NCT04901416
Safety and Efficacy of Allogeneic NK Cell Infusions in Patients With Relapsed/Refractory AML and High Risk MDS No drug interventions treatment 1 completed NCT04644016
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders treatment 2 recruiting NCT04730258
A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML treatment 1 / 2 recruiting NCT02167958
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source treatment 1 completed NCT05181735
Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA treatment 1 / 2 recruiting NCT05554835
Global Registry and Natural History Study for Mitochondrial Disorders No drug interventions Not Available Not Available recruiting NCT06326463
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies treatment 1 recruiting NCT04061239
Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML treatment 2 recruiting NCT00176839
Stem Cell Transplantation for Hematological Malignancies treatment 2 / 3 terminated NCT04110925
Mutational Analysis as a Prognostic and Predictive Marker of Cardiovascular (CVD) Disease in Patients With Myelodysplasia No drug interventions screening Not Available unknown_status NCT00176930
Stem Cell Transplant for Hematological Malignancy treatment Not Available terminated NCT01718366
A Study of Combined Deferasirox, Vitamin D and Azacytidine in High Risk MDS treatment 1 / 2 unknown_status NCT01379274
A Trial of Lenalidomide & Azacitidine in Low Risk Myelodysplastic Syndromes treatment 2 terminated NCT03466320
DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2 treatment 1 / 2 completed NCT00796562
Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy treatment 2 completed NCT04623944
NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS treatment 1 active_not_recruiting NCT03465540
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies treatment 1 terminated NCT01362140
Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) supportive_care 3 completed NCT00167167
Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia No drug interventions treatment Not Available completed NCT00973804
Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders treatment 1 terminated NCT00858572
STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders treatment 1 completed NCT00887068
Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129) treatment 3 completed NCT04017546
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS treatment 1 completed NCT01261312
SGI-110 in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) other 1 / 2 completed NCT02016781
Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102) No drug interventions treatment 2 completed NCT03138395
iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML No drug interventions Not Available Not Available withdrawn NCT00687414
Evaluation of Formin Gene Status and Expression in Myeloproliferative and Myelodysplastic Disorders No drug interventions Not Available Not Available completed NCT04749355
Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS treatment 2 unknown_status NCT03903055
Study on High-risk MDS Patients Based on RNA-seq Technology No drug interventions Not Available Not Available unknown_status NCT00684008
Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant treatment 1 completed NCT05175508
Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS treatment 2 / 3 unknown_status NCT02562443
Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA treatment 3 terminated NCT04898790
Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant No drug interventions treatment Not Available recruiting NCT00472290
Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS) treatment Not Available completed NCT00923364
Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC treatment 2 completed NCT05582902
Study Investigating Patient-Reported Outcomes in Lower-risk MDS Patients No drug interventions Not Available Not Available recruiting NCT05024877
Hetrombopag for Low/Intermediate-1 Risk MDS With Thrombocytopenia treatment 2 / 3 unknown_status NCT01192945
Non-interventional Study With Azacitidin (Vidaza®) No drug interventions Not Available Not Available completed NCT04187105
BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) treatment 2 recruiting NCT02226861
Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation prevention 1 completed NCT06533761
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML treatment 1 not_yet_recruiting NCT00462761
A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status treatment 1 completed NCT05177211
Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL) treatment 2 recruiting NCT03855371
Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS treatment 1 recruiting NCT06270771
OURA Ring Wearable Testing in MDS Patients: a Feasibility and Discovery Pilot Study No drug interventions Not Available Not Available not_yet_recruiting NCT00493571
Phase I Study of Gimatecan in Patients With Myelodysplastic Syndromes treatment 1 completed NCT01690507
Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML） treatment 1 / 2 completed NCT01535456
FLT-PET Imaging for MDS No drug interventions diagnostic Not Available terminated NCT01241500
Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts treatment 3 completed NCT03647800
Study of APVO436 in Patients With AML or MDS treatment 1 unknown_status NCT02418000
A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations treatment 1 / 2 terminated NCT01423175
ClAraC or FLAMSA Followed by Stem Cell Transplantation to Treat High Risk AML or Advanced MDS treatment 2 unknown_status NCT01133275
Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS treatment 2 completed NCT04511975
A Study Evaluating the Safety and Efficacy of IBI188 in Combination With AZA in Subjects With Newly Diagnosed MDS treatment 1 suspended NCT05796570
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies treatment 2 recruiting NCT00761449
Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5 treatment 2 completed NCT03275636
Haploidentical Donor vs mMUD in Hematological Malignancies No drug interventions treatment 2 / 3 completed NCT05740917
To Evaluate the Phase I Clinical Study of XZB-0004 in Patients With AML and MDS No drug interventions treatment 1 not_yet_recruiting NCT01019317
Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) treatment 2 completed NCT06552416
Safety of MT-401-OTS in Patients With Relapsed AML or MDS treatment 1 not_yet_recruiting NCT03745716
APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS) treatment 3 completed NCT02193958
Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies treatment 1 / 2 completed NCT04573686
Prognostic Value of Serum Erythropoietin Level,Ferritin Level and Fibrinogen in Adult Low Risk MDS Not Available Not Available unknown_status NCT02323139
A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients treatment 1 completed NCT00863148
Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL) treatment 2 completed NCT00692926
Unrelated Umbilical Cord Blood Transplantation Augmented With ALDHbr Umbilical Cord Blood Cells No drug interventions treatment 1 completed NCT05829226
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS) treatment 1 recruiting NCT00652626
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function other 1 completed NCT05153226
GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG prevention 3 recruiting NCT03526666
Ascorbic Acid Levels in MDS, AML, and CMML Patients No drug interventions Not Available Not Available completed NCT06211166
Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction No drug interventions Not Available Not Available recruiting NCT01584531
Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome treatment 2 completed NCT02197676
A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response treatment 2 completed NCT00440076
Velcade in Myelodysplastic Syndrome - Pilot Study treatment 2 terminated NCT02872662
Individual Molecular MRD Monitoring for MDS Patients After Allo-SCT No drug interventions Not Available Not Available unknown_status NCT02757989
Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk No drug interventions treatment Not Available completed NCT00185692
Allogeneic Transplantation From Related Haploidentical Donors treatment 2 completed NCT01342692
Best Promising Drug Association With Azacitidine in Higher Risk Myelodysplastic Syndromes treatment 2 unknown_status NCT00891592
Umbilical Cord Blood Transplant for Hematological Malignancies No drug interventions treatment 1 completed NCT00303472
Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS) treatment 2 completed NCT03050268
Familial Investigations of Childhood Cancer Predisposition No drug interventions Not Available Not Available recruiting NCT00815568
Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine, Busulfan, and Total Body Irradiation (TBI) treatment 2 unknown_status NCT02995655
CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia treatment 1 completed NCT05226455
Venetoclax in Patients With MDS or AML in Relapse After AHSCT treatment 1 / 2 recruiting NCT00614523
Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) supportive_care 2 completed NCT02985190
A Study of Azacitidine in Myelodysplastic Syndrome (MDS) Associated to Systemic Auto-immune and Inflammatory Disorders treatment 2 completed NCT04109690
CPX-351 in Patients Treated for Higher-risk Myelodysplastic Syndromes Experiencing Hypomethylating Agent Failure. No drug interventions treatment 1 / 2 withdrawn NCT01204164
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies treatment 1 completed NCT06156579
Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML treatment 2 recruiting NCT00990587
Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy treatment 1 completed NCT00593554
Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies treatment 2 terminated NCT02765997
StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies No drug interventions treatment 2 withdrawn NCT00212407
New York Blood Center National Cord Blood Program No drug interventions treatment 0 terminated NCT00511537
Unrelated Stem Cell Transplantation for Adults With Hematopoietic Disorders No drug interventions Not Available Not Available completed NCT00606437
Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants No drug interventions treatment 1 completed NCT00795132
Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies treatment 2 completed NCT00975975
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer treatment 2 completed NCT01904175
Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant No drug interventions Not Available Not Available completed NCT00513175
Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia No drug interventions Not Available Not Available completed NCT00578942
Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath treatment 2 completed NCT00580242
A Phase 1 Dose Escalating Trial of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplasia treatment 1 completed NCT00580034
Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath treatment 2 completed NCT04202835
ATG Plus PTCy vs ATG for CGVHD Prophylaxis prevention 2 recruiting NCT00514722
Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies No drug interventions treatment Not Available terminated NCT00136422
Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous Leukemia No drug interventions prevention 1 completed NCT00145626
HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies treatment 2 completed NCT05154474
Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy No drug interventions Not Available Not Available unknown_status NCT03314974
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders No drug interventions treatment 2 recruiting NCT00354120
Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant No drug interventions treatment 2 / 3 completed NCT01110473
ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies treatment 1 completed NCT05794880
MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing No drug interventions treatment Not Available recruiting NCT04166929
Haploidentical Stem Cell Transplant With or Without NK Cell Infusion in AML and MDS treatment 2 terminated NCT00963495
Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy treatment 1 terminated NCT02345850
Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301) prevention 3 completed NCT00899223
Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes No drug interventions Not Available Not Available active_not_recruiting NCT00594308
In-Vivo Activated T-Cell Depletion to Prevent GVHD treatment Not Available terminated NCT01297543
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia supportive_care 1 / 2 completed NCT01422603
Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML) treatment 1 / 2 completed NCT00506402
A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies treatment 1 completed NCT02338479
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies No drug interventions Not Available Not Available active_not_recruiting NCT04173533
Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT treatment 3 active_not_recruiting NCT00195533
Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients Not Available Not Available completed NCT03674411
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy treatment 2 active_not_recruiting NCT01911871
Multicenter Observational Study on Myocardial Iron Overload in 3 Multitransfused Populations No drug interventions Not Available Not Available completed NCT02208037
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) prevention 2 completed NCT00516152
Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT treatment 2 completed NCT03387475
Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents treatment 2 recruiting NCT01956799
Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy No drug interventions Not Available Not Available completed NCT05223699
Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB) No drug interventions treatment 1 terminated NCT01962636
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases treatment Not Available recruiting NCT00513318
Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic Malignancies No drug interventions Not Available Not Available terminated NCT00862719
Sitagliptin Umbilical Cord Blood Transplant Study treatment 2 completed NCT03959241
TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801) prevention 3 completed NCT05735717
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies treatment 2 recruiting NCT04800458
Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis No drug interventions diagnostic Not Available recruiting NCT01933035
Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias. No drug interventions Not Available Not Available completed NCT02007863
Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia treatment Not Available completed NCT00434239
Lenalidomide and Recombinant Human Stem Cell Factor for Treatment of Myelodysplasia treatment 0 unknown_status NCT01095874
Allogeneic Hematopoietic Stem Cell Transplantation Evaluation in High Risk Myelodysplasia: an Observational Non-interventional Study No drug interventions Not Available Not Available completed NCT03613727
Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients treatment 2 completed NCT03480360
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression treatment 3 active_not_recruiting NCT02323867
Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies No drug interventions treatment 2 recruiting NCT00740181
Decitabine, Cytarabine, GCSF for Refractory AML/MDS No drug interventions treatment 2 terminated NCT00597714
Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant No drug interventions treatment 2 completed NCT00109538
Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED) treatment 3 terminated NCT05260203
MargheRITA (Remote Intelligence for Therapeutic Adherence) No drug interventions supportive_care Not Available completed NCT03431090
Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic Malignancies and Myelodysplasia No drug interventions treatment 1 / 2 active_not_recruiting NCT01338987
Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation treatment 2 completed NCT00956787
Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS) treatment 2 unknown_status NCT00582933
Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor treatment 2 completed NCT04195633
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies treatment 2 recruiting NCT03683433
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation treatment 2 recruiting NCT00620633
Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation No drug interventions treatment 1 completed NCT02000154
Long Term Safety Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study No drug interventions treatment 1 completed NCT04708054
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS treatment 2 recruiting NCT03268954
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) treatment 3 active_not_recruiting NCT00050154
Study of Tipifarnib in Patients With High-Risk Myelodysplastic Syndrome (MDS) treatment 2 completed NCT02279654
Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q) Not Available Not Available completed NCT02999854
Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer prevention 3 terminated NCT01250951
This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload. treatment 4 completed NCT01621477
T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant treatment 2 terminated NCT00807677
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies treatment 1 completed NCT02783547
Combination Therapy of SyB C-1101 and Azacytidine in Patients With Myelodysplastic Syndrome treatment 1 withdrawn NCT00495547
SIMIDIS: Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome treatment 2 terminated NCT04279847
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms treatment 1 recruiting NCT01326845
Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study treatment 4 terminated NCT01768845
Unrelated Umbilical Cord Blood (UBC)Transplantation No drug interventions treatment Not Available completed NCT00806598
Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome treatment 2 completed NCT02085798
Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment) No drug interventions Not Available Not Available completed NCT01823198
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies treatment 1 / 2 completed NCT01188798
Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies treatment 3 completed NCT01611298
Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR prevention Not Available completed NCT00329498
L-Ascorbic Acid Depletion to Treat Acute Myeloid Leukemia and Myelodysplastic Syndromes treatment 2 suspended NCT02117297
SCT Plus Immune Therapy in Average Risk AML/MDS treatment 2 completed NCT00004997
Leucovorin for the Treatment of 5 q Minus Syndrome treatment 2 completed NCT02226497
Telemonitoring Device in Managing Outpatient Care of Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia After Intensive Chemotherapy No drug interventions device_feasibility Not Available terminated NCT06355583
Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial No drug interventions prevention 2 not_yet_recruiting NCT01500161
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match treatment 2 terminated NCT00965861
SCRI Tissue Testing Registry No drug interventions Not Available Not Available terminated NCT01985061
Evaluation of 3 Different Doses of IV Busulfan treatment 2 unknown_status NCT03365661
QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML treatment 2 withdrawn NCT01619761
NK Cells in Cord Blood Transplantation treatment 1 unknown_status NCT04802161
Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes treatment 2 suspended NCT00067028
Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML) treatment 2 completed NCT01749111
Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis prevention 3 terminated NCT00658411
Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation prevention Not Available terminated NCT01602211
INSPIRE: Internet and Social-media Program With Information and Resources for Long-Term Cancer Survivors Who Underwent Stem Cell Transplant No drug interventions supportive_care 3 completed NCT01300611
TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation supportive_care 1 terminated NCT00251511
A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With Myelodysplastic Syndrome treatment 2 terminated NCT02007811
Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination No drug interventions treatment 1 / 2 unknown_status NCT03047993
Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome treatment 1 / 2 completed NCT03404193
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome treatment 2 active_not_recruiting NCT04537871
Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study No drug interventions Not Available Not Available recruiting NCT01462578
Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza) treatment 2 completed NCT02272478
Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations treatment 2 / 3 unknown_status NCT02767388
Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery No drug interventions Not Available Not Available completed NCT03622788
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant treatment 1 / 2 recruiting NCT00719888
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease treatment 2 active_not_recruiting NCT06492707
DR-18 for the Treatment of Relapsed or Persistent Acute Myeloid Leukemia or Myelodysplastic Syndrome After Hematopoietic Cell Transplantation, the DR. DREAM Trial No drug interventions treatment 1 recruiting NCT03661307
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome treatment 1 / 2 recruiting NCT00941109
Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS) treatment 1 completed NCT00852709
Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias treatment 1 terminated NCT05457556
Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome treatment 3 recruiting NCT04243785
A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome treatment 1 recruiting NCT02057185
Occupational Status and Hematological Disease No drug interventions Not Available Not Available completed NCT01196715
Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes Not Available 3 unknown_status NCT00510315
Abdominal Obesity and Cardiovascular Risk Factors in Women Who Survived Cancer or a Related Illness Following Total Body Irradiation and Stem Cell Transplant No drug interventions Not Available Not Available completed NCT00005937
Antithymocyte Globulin and Cyclosporine to Treat Myelodysplasia treatment 2 completed NCT03094637
Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome treatment 2 active_not_recruiting NCT02250937
Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome treatment 2 active_not_recruiting NCT04484532
Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers supportive_care 0 completed NCT02436252
Study of DSP-7888 in Patients With Myelodysplastic Syndrome No drug interventions treatment 1 / 2 completed NCT04160052
Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome treatment 1 / 2 recruiting NCT02936752
Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents treatment 1 active_not_recruiting NCT03560752
CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant supportive_care 1 active_not_recruiting NCT05453552
G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT treatment 2 / 3 recruiting NCT01739452
Spanish Registry of Erythropoietic Stimulating Agents Study No drug interventions Not Available Not Available completed NCT01812252
Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant treatment 2 completed NCT00689000
Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM) treatment 1 / 2 completed NCT00443300
Effectiveness of Protected Environment Rooms for AML and MDS No drug interventions Not Available Not Available terminated NCT00939159
Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) treatment 2 terminated NCT02356159
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation treatment 1 / 2 active_not_recruiting NCT01141959
Blood Samples to Identify Biomarkers in Haploidentical Graft Recipients No drug interventions Not Available Not Available completed NCT00570375
The Role of Erlotinib an Epidermal Growth Factor Receptor (EGFR) Inhibitor in the Treatment of Myelodysplastic Syndrome treatment 2 withdrawn NCT00778375
Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) treatment 2 completed NCT04762875
MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies treatment 2 terminated NCT06128070
Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome prevention 2 recruiting NCT01593670
Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes treatment 2 completed NCT04761770
Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders No drug interventions treatment 2 active_not_recruiting NCT02706899
Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS treatment 1 / 2 terminated NCT06329999
A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML No drug interventions treatment Not Available recruiting NCT00723099
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer treatment 2 completed NCT04281199
TBI Using IMRT (VMAT or Tomotherapy) for the Prevention of Pul Toxicities in Patients Undergoing Donor SCT No drug interventions treatment 1 active_not_recruiting NCT01794299
Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor No drug interventions prevention 2 completed NCT00282399
A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome treatment 1 terminated NCT00570999
Palifermin After Haploidentical PBSCT treatment 2 withdrawn NCT03246906
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation treatment 2 active_not_recruiting NCT00071006
AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS) treatment 2 completed NCT01053806
Safety And Efficacy Of Azacitidine, and Lenalidomide In Higher Risk Myelodysplastic Syndrome treatment 2 unknown_status NCT01333449
Study of Decitabine Induction Prior to Allogeneic Hematopoietic Cell Transplant in Newly Diagnosed MDS Patients treatment 2 terminated NCT00818649
Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia treatment 2 terminated NCT02123836
Natural Killer Cells in Acute Leukaemia and Myelodysplastic Syndrome treatment 1 unknown_status NCT01904136
Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia treatment 1 / 2 completed NCT01745913
Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies treatment 2 terminated NCT02121418
Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm treatment Not Available completed NCT03358719
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia treatment 1 completed NCT01168219
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia treatment 2 completed NCT01048619
Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome treatment 1 completed NCT00597519
A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy treatment 2 completed NCT02117219
Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome treatment 1 completed NCT00954941
Ondansetron Versus Aprepitant Plus Ondansetron for Emesis treatment 2 completed NCT01272817
Nonmyeloablative Allogeneic Transplant No drug interventions treatment Not Available completed NCT01200017
Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant No drug interventions Not Available Not Available no_longer_available NCT01099917
Does Maitake Mushroom Extract Enhance Hematopoiesis in Myelodysplastic Patients? treatment 2 completed NCT02861417
Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant treatment 2 active_not_recruiting NCT01634217
Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation No drug interventions treatment 1 completed NCT06419634
Study of BMS-986497 (ORM-6151) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome No drug interventions treatment 1 recruiting NCT01048034
Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) treatment 2 completed NCT00491634
Treosulfan-based Conditioning for Transplantation in AML/MDS treatment 2 completed NCT02396134
Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant No drug interventions supportive_care 2 active_not_recruiting NCT00378534
Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants treatment 2 completed NCT02075034
Three Dosing Schedules of Oral Rigosertib in MDS Patients treatment 1 withdrawn NCT00598624
Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) treatment 2 unknown_status NCT00459524
Quality of Life of Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) No drug interventions Not Available Not Available completed NCT00606216
Structural Imaging and Cognitive Functions in Adult Stem Cell Transplant Recipients Treated With Chemotherapy Alone or in Combination With Radiotherapy No drug interventions Not Available Not Available completed NCT00498316
Cord Blood Expansion on Mesenchymal Stem Cells treatment 1 completed NCT03970096
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) treatment 2 recruiting NCT01709396
ED-TBI Followed By Allogeneic Stem Cell Transplantation For The Treatment Of Refractory AML And Advanced MDS No drug interventions treatment 2 suspended NCT00048958
Cytogenetic Studies in Acute Leukemia and Multiple Myeloma No drug interventions Not Available Not Available active_not_recruiting NCT01491958
Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation supportive_care 2 completed NCT00402558
Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) treatment 1 completed NCT02890758
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 treatment 1 completed NCT01819558
Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy No drug interventions treatment 1 / 2 completed NCT01700335
Safety and Pharmacokinetics Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) No drug interventions treatment 1 completed NCT02458235
Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation treatment 2 completed NCT02530463
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome treatment 2 active_not_recruiting NCT00852163
Study of Stem Cell Transplant for Leukemia and Myelodysplastic Syndromes Using Clofarabine and Busulfan Regimen treatment 2 completed NCT06063486
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms No drug interventions treatment 2 recruiting NCT01133886
Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure treatment 2 unknown_status NCT02923986
Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS treatment 1 / 2 withdrawn NCT00045786
Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes treatment 2 completed NCT03333486
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer treatment 2 active_not_recruiting NCT03019939
Isavuconazole in Preventing Invasive Fungal Infections in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome and Neutropenia prevention 2 completed NCT03672539
Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome treatment 2 recruiting NCT01757639
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia treatment 1 completed NCT00903422
Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS) treatment 1 completed NCT02850822
Effect of Chemotherapy vs No Chemotherapy Pre-transplant to MDS Undergoing Allo-HSCT No drug interventions Not Available Not Available unknown_status NCT01598025
Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor treatment Not Available terminated NCT00897130
5-Azacitidine in Low-risk Myelodysplastic Syndromes (MDSs) treatment 2 completed NCT00520130
Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System treatment 1 / 2 completed NCT00977548
Erlotinib Study for Myelodysplastic Syndrome (MDS) treatment 2 completed NCT02381548
Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia treatment 1 terminated NCT00656448
A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS supportive_care 3 completed NCT03862157
Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia treatment 1 / 2 active_not_recruiting NCT01063257
Clofarabine in High Risk Myelodysplastic Syndrome (MDS) treatment 1 / 2 completed NCT02017457
Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation. treatment 2 completed NCT00626626
Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation treatment 1 / 2 terminated NCT01663766
Phase I Study of Milatuzumab for Graft Versus Host Disease treatment 1 terminated NCT03066466
Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT prevention 3 withdrawn NCT01433965
Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome treatment 1 completed NCT00260065
A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic Syndromes treatment 2 completed NCT02719574
Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation treatment 1 / 2 completed NCT01249820
Pharmacokinetics of Anidulafungin (Ecalta ®) Intravenous Given to Patients at High Risk for Developing Invasive Fungal Disease other 2 completed NCT02042482
The Effect of Combination Ultra Q10 and L-carnitine on the Course of Myelodysplastic Syndrome No drug interventions treatment 2 / 3 unknown_status NCT00153582
WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML) No drug interventions treatment 2 unknown_status NCT00843882
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia treatment 3 active_not_recruiting NCT02556931
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies treatment 2 completed NCT00038831
Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS treatment 1 / 2 completed NCT00057031
Study of High-Dose Pulse Administration DN-101 (Calcitriol) in Patients With Myelodysplastic Syndrome (MDS) treatment 2 unknown_status NCT03399773
Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes treatment 2 recruiting NCT00001873
The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers No drug interventions treatment 2 completed NCT06498973
Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant treatment 1 not_yet_recruiting NCT01010373
Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients treatment 2 suspended NCT02842827
A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001) treatment 1 / 2 completed NCT02520427
A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies treatment 1 terminated NCT00809276
Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY treatment 1 / 2 completed NCT01207076
AHN-12 Biodistribution in Advanced Leukemia No drug interventions treatment 1 terminated NCT06073860
A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemia Not Available Not Available recruiting NCT05969860
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer No drug interventions health_services_research 2 recruiting NCT01305460
Intensified Azacitidine in High Risk Myelodysplastic Syndrome (MDS) treatment 1 / 2 completed NCT03359460
Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome treatment 1 completed NCT03471260
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies treatment 1 / 2 recruiting NCT00460694
Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies No drug interventions treatment 1 / 2 completed NCT00588991
Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders treatment 1 active_not_recruiting NCT02363491
A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome treatment 1 / 2 completed NCT06195891
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome treatment 1 recruiting NCT02169791
Nonmyeloablative Haploidentical Transplant Followed by MLN9708 prevention 2 completed NCT02737462
Phase 1/2 Study of CG200745 PPA for Myelodysplastic Syndrome treatment 1 / 2 active_not_recruiting NCT06484062
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 and ASTX727 With Venetoclax to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes treatment 1 not_yet_recruiting NCT01572662
Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning treatment 2 completed NCT05364762
Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants prevention 2 recruiting NCT03356080
DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess treatment 2 unknown_status NCT00774280
Busulfan Plus Cyclophosphamide vs Fludarabine as a Conditioning Regimen treatment 3 completed NCT00987480
Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine treatment 2 completed NCT01541280
VIDAZA-DLI Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome treatment 2 completed NCT04013880
ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia treatment 1 / 2 withdrawn NCT05823480
Magrolimab in Combination With Azacitidine After Allogeneic HCTin Treating Patients With High-Risk AML or MDS treatment 1 suspended NCT03770429
AZD6738 for Patients With Progressive MDS or CMML treatment 1 recruiting NCT02137629
Post Marketing Surveillance to Collect and Evaluate the Safety and Efficacy Information of Korean MDS Patients Treated With VIDAZA®, After Approval of Marketing Authorization for New Drug in Korea Not Available Not Available completed NCT01885689
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia treatment 2 active_not_recruiting NCT02330692
Cohort Study of New Prognostic Factors With Peripheral Blood and Bone Marrow Evaluation at the Time of Diagnosis and Relapse in Myelodysplastic Syndrome No drug interventions Not Available Not Available unknown_status NCT01953692
A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) treatment 1 completed NCT00709592
Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT treatment 2 completed NCT03438344
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant supportive_care 2 withdrawn NCT01399840
Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies treatment 1 completed NCT00809367
Collection and Banking of Leukemia Cells MDS/AML No drug interventions Not Available Not Available completed NCT00299767
Phase I Study of Sequential Cord Blood Transplants No drug interventions treatment 1 completed NCT02494167
Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) No drug interventions treatment 1 recruiting NCT05316701
Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies No drug interventions treatment 3 active_not_recruiting NCT04339101
Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation treatment 2 active_not_recruiting NCT01804101
Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia treatment Not Available completed NCT00704704
Safety and Efficacy of Azacitidine, and Thalidomide in Higher Risk MDS (Myelodysplastic Syndrome) treatment 2 unknown_status NCT00195104
Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML treatment 1 / 2 completed NCT04842604
Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML treatment 3 completed NCT01451268
Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) treatment 1 / 2 unknown_status NCT02722668
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep treatment 2 active_not_recruiting NCT02943668
Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome treatment 2 terminated NCT03494569
Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome treatment 1 recruiting NCT02065869
Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant treatment 1 / 2 terminated NCT02319369
Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) treatment 1 terminated NCT03969446
Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory treatment 1 recruiting NCT01615146
Outpatient Platelet Transfusions in Myelodysplastic Syndromes and Leukemia: The OPTIMAL Pilot No drug interventions treatment Not Available terminated NCT00774046
High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML treatment 2 completed NCT02262312
Iron Overload and Transient Elastography in Patients With Myelodysplastic Syndrome No drug interventions Not Available Not Available completed NCT01169012
PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias basic_science 1 completed NCT01366612
PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation treatment 3 terminated NCT01231412
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant treatment 3 completed NCT00467610
Phase 2, Open-Label, Multi-Dose Study of Panhematin in Patients With MDS treatment 2 terminated NCT00043810
Study of Gelonin Purging of Autologous Stem Cells for Transplantation treatment 1 / 2 terminated NCT01295710
Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) No drug interventions prevention 3 completed NCT00043381
Decitabine Versus Supportive Care in Adults With Advanced-stage MDS treatment 3 completed NCT00270881
Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies treatment 1 / 2 completed NCT03800095
Early Palliative Care for Patients With Haematological Malignancies No drug interventions treatment 3 unknown_status NCT01773395
GVAX vs. Placebo for MDS/AML After Allo HSCT treatment 2 terminated NCT02750995
Peptide Vaccination in Combination With Azacitidine for Patients With MDS and AML treatment 1 completed NCT00283114
A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome treatment 1 completed NCT00721214
5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic Syndrome treatment 2 completed NCT04515914
Clinical Relevance of DNMT and HDAC Gene SNP on the Response to Decitabine Therapy for Myelodysplastic Syndrome No drug interventions Not Available Not Available completed NCT05823714
Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT No drug interventions treatment 2 recruiting NCT00368355
T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts treatment 2 completed NCT04655755
Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia treatment 1 / 2 recruiting NCT03600155
Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome treatment 1 active_not_recruiting NCT01586455
Human Placental-Derived Stem Cell Transplantation No drug interventions treatment 1 completed NCT05564650
Evaluating Navitoclax After Failure of Standard Treatments of Azacitidine or Decitabine and Venetoclax in Patients With Aggressive Myelodysplastic Syndrome treatment 1 / 2 recruiting NCT02500550
Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor prevention 2 completed NCT01683123
Study With Intravenous Busulfan And Fludarabine Myeloablative Conditioning Regimen For HLA Identical Sibling Donor HSCT No drug interventions Not Available Not Available completed NCT00001623
Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia No drug interventions treatment Not Available completed NCT06013423
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases treatment 2 recruiting NCT02676323
Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome treatment 1 terminated NCT01673308
Lenalidomide After Failure of Hypomethylating Agents in Myelodysplastic Syndrome treatment 2 unknown_status NCT00067808
Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS) treatment 2 completed NCT04994808
Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia treatment 2 recruiting NCT04146038
Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease treatment 2 completed NCT02678338
CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies treatment 1 completed NCT02508038
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors treatment 1 recruiting NCT03072043
Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms treatment 1 / 2 completed NCT00967343
Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor No drug interventions prevention 2 / 3 terminated NCT03113643
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) treatment 1 recruiting NCT00466843
Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome treatment 2 unknown_status NCT00144703
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation prevention 2 completed NCT01331603
Assessment of Labile Plasma Iron (LPI) in Myelodysplastic Syndromes (MDS) and Primary Myelofibrosis No drug interventions Not Available Not Available unknown_status NCT01494103
Administration of Donor T Cells With the Caspase-9 Suicide Gene treatment 1 active_not_recruiting NCT02258490
Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation Not Available Not Available no_longer_available NCT03154190
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer No drug interventions health_services_research Not Available unknown_status NCT00669890
Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML treatment 1 terminated NCT02188290
Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation No drug interventions Not Available Not Available completed NCT00382590
Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients treatment 2 completed NCT04734990
Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia treatment 1 / 2 recruiting NCT00074490
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers treatment 2 terminated NCT01062490
Treosulfan Based Conditioning Myelodysplastic Syndrome (MDS) treatment 2 completed NCT04493164
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome treatment 2 recruiting NCT01716364
Safety Study of Anti LewisY Chimeric Antigen Receptor in Myeloma, Acute Myeloid Leukemia or Myelodysplastic Syndrome No drug interventions treatment 1 unknown_status NCT00968864
T-cell Depleted Alternative Donor Transplantation No drug interventions treatment 2 terminated NCT02719821
Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation No drug interventions supportive_care Not Available completed NCT00113321
Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure treatment 2 terminated NCT01290302
Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza® in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia treatment 1 completed NCT00882102
Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS) treatment 2 completed NCT02013102
A Phase Ⅳ Study of Decitabine in Myelodysplastic Syndrome treatment 4 unknown_status NCT01277484
Dose Finding Study of Post-BMT Decitabine Maintenance Treatment in Higher-risk MDS and MDS/AML treatment 1 unknown_status NCT02717884
Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP) treatment 1 / 2 unknown_status NCT00697684
Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant treatment 1 completed NCT02732184
A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS treatment 2 completed NCT01252784
Reduced-intensity Conditioning Allogeneic Hematopoietic Cell Transplantation No drug interventions Not Available Not Available unknown_status NCT00064584
Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML) treatment 1 completed NCT04635384
Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test No drug interventions Not Available Not Available recruiting NCT00760084
Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome treatment 2 completed NCT00101179
MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia treatment 1 completed NCT00674479
INCB018424 in Patients With Advanced Hematologic Malignancies treatment 2 completed NCT02543879
Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies treatment 1 completed NCT04282187
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms treatment 2 recruiting NCT01926587
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine treatment 1 / 2 completed NCT02506933
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant supportive_care 2 active_not_recruiting NCT03272633
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies No drug interventions treatment 0 terminated NCT00374933
Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation No drug interventions treatment 1 completed NCT00013533
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies No drug interventions treatment 0 completed NCT00587054
Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders No drug interventions treatment 2 completed NCT02045654
Platelet Response During the Second Cycle of Decitabine Can Predict Response and Survival for Myelodysplastic Syndrome No drug interventions Not Available Not Available unknown_status NCT02750254
Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation treatment 1 terminated NCT02065154
Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis prevention 2 completed NCT02431351
Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients treatment 2 withdrawn NCT00418951
Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections prevention 2 completed NCT02014051
Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) No drug interventions treatment 1 completed NCT03337451
Follow up Protocol to the Phase I/II Study of OPN-305 in Second-line or Third-line Lower Lower Risk Myelodysplastic Syndrome treatment 1 / 2 completed NCT00392353
Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia treatment 1 / 2 active_not_recruiting NCT01556477
The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q). treatment 2 unknown_status NCT01894477
Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia treatment 2 unknown_status NCT02877277
Epigenetics, Vitamin C and Abnormal Hematopoiesis - Pilot Study No drug interventions treatment Not Available completed NCT05972577
Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study No drug interventions supportive_care Not Available active_not_recruiting NCT04060277
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation supportive_care 2 active_not_recruiting NCT04227847
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies treatment 1 recruiting NCT05061147
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) treatment 1 / 2 unknown_status NCT00854945
Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML treatment 1 / 2 completed NCT01291745
Collection of Biological Data With Potential Prognostic Relevance in Patients With MYELODYSPLASTIC SYNDROMES No drug interventions Not Available Not Available unknown_status NCT00433745
Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy No drug interventions treatment 2 completed NCT02929498
Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS) treatment 1 / 2 terminated NCT01855698
PENELOPE Observational Study: Prophylaxis and Treatment of Arterial and Venous Thromboembolism No drug interventions Not Available Not Available completed NCT00900198
Collection of Tissue Samples for Cancer Research No drug interventions Not Available Not Available recruiting NCT03602898
Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation treatment 2 withdrawn NCT01624805
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome treatment 2 recruiting NCT03192397
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant treatment 1 / 2 active_not_recruiting NCT01664897
Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia treatment 2 completed NCT00893997
PR1 Vaccination in Myelodysplastic Syndrome (MDS) treatment 2 terminated NCT01696461
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor treatment 2 completed NCT00867061
Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS) treatment 1 / 2 withdrawn NCT02935361
Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed treatment 1 / 2 active_not_recruiting NCT00136461
A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) treatment 2 completed NCT00113828
Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies No drug interventions treatment 2 terminated NCT01159028
Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS treatment 1 completed NCT01685411
Busulfan and Cyclophosphamide Followed By ALLO BMT treatment Not Available terminated NCT02360111
GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant treatment Not Available terminated NCT02743611
Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma treatment 1 / 2 terminated NCT00822393
Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC) treatment 3 completed NCT00875693
A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML) No drug interventions treatment 1 completed NCT02521493
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome treatment 3 active_not_recruiting NCT00697671
Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies treatment 1 completed NCT00968071
Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome treatment 2 completed NCT01003678
Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients treatment 1 terminated NCT04188678
Resiliency in Older Adults Undergoing Bone Marrow Transplant No drug interventions other Not Available active_not_recruiting NCT01339988
Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT) treatment 4 unknown_status NCT01174888
Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia treatment 1 completed NCT02581007
Reduced Intensity Conditioning Transplant Using Haploidentical Donors treatment 2 completed NCT03088709
Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide prevention 2 terminated NCT02060409
Prognostic Molecular Markers in Patients With Myelodysplastic Syndrome No drug interventions Not Available Not Available completed NCT04713956
G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT treatment 2 / 3 unknown_status NCT00299156
Oral Clofarabine Study in Patients With Myelodysplastic Syndrome treatment 2 completed NCT00686556
Total Marrow Irradiation for Refractory Acute Leukemia treatment 1 completed NCT01980056
Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy treatment 1 / 2 completed NCT02367456
A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients treatment 1 completed NCT01362985
Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off-Label Transplant Use of Plerixafor No drug interventions Not Available Not Available completed NCT04022785
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome treatment 1 completed NCT01951885
Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention supportive_care 3 completed NCT03939585
Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT No drug interventions treatment 1 not_yet_recruiting NCT02492737
Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation treatment 1 completed NCT00648037
Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT treatment Not Available completed NCT00001637
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults No drug interventions treatment 2 completed NCT00422032
2 Arm Study of Clofarabine IV in MDS Patients treatment 2 completed NCT00306332
T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation No drug interventions treatment 3 terminated NCT02598752
Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell Transplantation No drug interventions Not Available Not Available completed NCT01062152
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS) treatment 1 completed NCT00556452
Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen treatment 1 / 2 completed NCT03086252
Patient-Driven Transfusion Thresholds in Hematological Disorders: A Pilot Study No drug interventions supportive_care Not Available withdrawn NCT02663752
A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy. basic_science 2 terminated NCT04451200
Sequential and Personalized PK-guided Busulfan Administration in the Frame of the Conditiong Regimen for Allo-HSCT in Patients With Malignant Hemopathies Ineligible for the Standard Myeloablative Conditioning treatment 2 not_yet_recruiting NCT00195000
Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS treatment 2 completed NCT01509300
HLA-haploidentical Hematopoietic Stem Cell Transplantation for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid Tumors treatment 1 / 2 unknown_status NCT00943800
Combined Haploidentical-Cord Blood Transplantation for Adults and Children treatment Not Available completed NCT00143559
Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies No drug interventions treatment 2 completed NCT00285259
Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) No drug interventions treatment 2 completed NCT02639559
Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies treatment 2 completed NCT03128359
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant supportive_care 2 completed NCT00458159
A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes No drug interventions treatment 1 terminated NCT01356875
Treatment of Myelodysplastic Syndromes Comparing Hydralazine/Ac. Valproic and Supportive Care in Patients Not Candidates, Refractory and/or Intolerant to Intensive Chemotherapy treatment 2 unknown_status NCT01020175
Peripheral Blood (PB) Versus Bone Marrow (BM) in Allogeneic Stem Cell Transplantation No drug interventions treatment 3 completed NCT00326170
Phase II 5-Azacytidine Plus VPA Plus ATRA treatment 2 completed NCT06034470
Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms treatment 1 recruiting NCT04083170
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers treatment 2 terminated NCT02744742
G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT treatment 2 / 3 completed NCT02296242
Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes treatment 1 / 2 completed NCT05448599
A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS No drug interventions treatment 1 / 2 recruiting NCT02181699
Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) No drug interventions treatment 1 terminated NCT00619099
A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) treatment 2 completed NCT01455506
PRO#0118: Decitabine Plus Mini Flu-Bu treatment 1 completed NCT04439006
Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization treatment 1 completed NCT01746849
Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation treatment 2 active_not_recruiting NCT00488436
Antithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With Myelodysplastic Syndrome treatment 4 completed NCT01736436
APG101 in Myelodysplastic Syndrome treatment 1 completed NCT02002936
Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study No drug interventions treatment 1 completed NCT01370213
NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases treatment 2 completed NCT00088218
Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS). diagnostic 2 completed NCT00350818
Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT) treatment 1 completed NCT04859218
Revisiting the Universal Donor: Does Exposure to O Blood Products Affect Patient Outcomes? No drug interventions treatment Not Available recruiting NCT01597219
Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers No drug interventions treatment 2 completed NCT01828619
Study of New RIC Regimen of BuFlu in Older and/or Intolerable Patients No drug interventions Not Available Not Available unknown_status NCT01255319
Cyclophosphamide, Fludarabine and Antithymocyte Globulin Conditioning in Myelodysplastic Syndrome (MDS) No drug interventions Not Available Not Available unknown_status NCT03816319
TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Refractory Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia treatment 1 not_yet_recruiting NCT00739141
Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies. treatment 2 completed NCT01404741
5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS) No drug interventions treatment 2 completed NCT04691141
A Study to Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS) No drug interventions treatment 1 / 2 terminated NCT04726241
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study No drug interventions screening 1 / 2 recruiting NCT06577441
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) treatment 2 not_yet_recruiting NCT01513317
A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome treatment 2 terminated NCT00741234
A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine treatment 1 completed NCT00906334
Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk treatment 2 completed NCT02508324
IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia No drug interventions treatment 2 terminated NCT01795924
Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome No drug interventions treatment 1 / 2 terminated NCT01028716
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies treatment 2 terminated NCT00089596
Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers No drug interventions treatment 1 / 2 completed NCT00640796
Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors treatment 1 completed NCT04079296
A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS) No drug interventions treatment 1 / 2 completed NCT04167696
Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02 treatment 1 recruiting NCT02807558
A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome treatment 2 completed NCT01311258
Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome No drug interventions Not Available Not Available recruiting NCT02485535
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant treatment 1 completed NCT00152139
Stem Cell Transplantation for Patients With Hematologic Malignancies No drug interventions treatment 3 completed NCT01020539
Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia treatment 1 completed NCT05010122
ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome treatment 1 / 2 recruiting NCT02809222
Plasmatic L-AScorbic Acid in MYelodyplastic Syndroms and Controls No drug interventions health_services_research Not Available completed NCT02046122
Adoptive Transfer of Haplo-identical DLI for AML and MDS treatment 1 / 2 completed NCT02203825
Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands No drug interventions treatment 1 completed NCT01240525
Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers No drug interventions treatment 2 unknown_status NCT00967525
Intraosseous Infusion of Unrelated Cord Blood Grafts No drug interventions treatment Not Available terminated NCT01075425
Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome treatment 1 completed NCT04666025
SARS-CoV-2 Donor-Recipient Immunity Transfer No drug interventions Not Available Not Available completed NCT05115630
Off-the-shelf NK Cells + SCT for Myeloid Malignancies treatment 1 / 2 recruiting NCT01951430
Observational Evaluation of Infective Risk in Myelodysplastic Syndrome Patients Not Available Not Available completed NCT00867230
FTS Study in Patients With Advanced Hematologic Malignancies No drug interventions treatment 1 completed NCT00487448
SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia treatment 4 completed NCT00795548
Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation treatment 2 completed NCT01111448
Temsirolimus in Myelodysplastic Syndrome (MDS) treatment 2 terminated NCT00506948
Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD) treatment 2 terminated NCT01834248
DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia treatment 1 completed NCT02464657
Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) treatment 1 / 2 completed NCT04239157
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia treatment 2 recruiting NCT00744757
An Efficacy and Safety Study of Decitabine in Participants With Myelodysplastic Syndrome (MDS) treatment 2 completed NCT01682226
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies treatment 2 completed NCT02018926
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS treatment 1 / 2 completed NCT00960726
NOV-002 in Myelodysplastic Syndrome (MDS) treatment 2 withdrawn NCT00247026
The Efficacy of Coenzyme Q10 And Curcumin in Patients With Myelodysplastic Syndromes treatment 1 / 2 withdrawn NCT00831766
Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) treatment 1 / 2 completed NCT02447666
Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML) treatment 2 completed NCT01119066
HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies treatment 2 completed NCT00110266
Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients treatment 2 completed NCT00911066
MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia treatment 1 completed NCT03303066
Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS) treatment 2 / 3 completed NCT00672165
Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies treatment 1 completed NCT02291965
Blood Samples to Identify Biomarkers of Busulfan No drug interventions Not Available Not Available active_not_recruiting NCT03092674
Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome treatment 2 / 3 active_not_recruiting NCT03017820
VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma treatment 1 recruiting NCT01690520
Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes treatment 2 completed NCT01323920
Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors treatment 2 completed NCT00324220
A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia treatment 1 / 2 completed NCT00504920
Symptom-Related Cytokines in Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Patients No drug interventions Not Available Not Available completed NCT00304720
Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor treatment 2 unknown_status NCT02397720
Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia treatment 2 completed NCT01481220
Safety Study of Eltrombopag Combined With Azacitidine to Treat Myelodysplastic Syndrome (MDS) treatment 1 completed NCT00954720
Observational Study of Iron Overload in Stem Cell Transplantation No drug interventions Not Available Not Available completed NCT00044382
Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome treatment 2 completed NCT03096782
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma treatment 2 completed NCT02129582
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies treatment 1 completed NCT02877082
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients prevention 2 terminated NCT01700673
Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS treatment 2 completed NCT00674427
Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant No drug interventions treatment 1 terminated NCT03724227
Expanded Access for ACE-011 Not Available Not Available no_longer_available NCT00840827
Efficacy and Safety of Lenalidomide in Combination With Cyclosporine A in Patients With Myelodysplastic Syndromes treatment 2 terminated NCT01243476
Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome treatment 3 completed NCT01522976
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia treatment 2 active_not_recruiting NCT00903760
Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS) treatment 2 completed NCT00452660
Evaluation the Effect of Exjade on Oxidative Stress in Low Risk Myelodysplastic Syndrome Patients With Iron Over Load treatment 4 completed NCT00412360
Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501) treatment 3 completed NCT05600894
Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm treatment 2 recruiting NCT03630991
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy treatment 1 recruiting NCT06059391
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant treatment 2 recruiting NCT02684162
Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant treatment 2 active_not_recruiting NCT01930162
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant basic_science 2 completed NCT01398462
Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients No drug interventions treatment 1 completed NCT00167180
Post Transplant Donor Lymphocyte Infusion treatment 2 terminated NCT00764829
Blood Samples to Evaluate Biomarkers of Donor Chimerism No drug interventions Not Available Not Available completed NCT01135329
Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers treatment 2 terminated NCT00710892
CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene No drug interventions treatment 1 active_not_recruiting NCT00469144
IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome treatment 3 completed NCT06287944
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome treatment 1 not_yet_recruiting NCT01542944
TevaGastrim for Stem Cell Mobilization Sibling Donors treatment 2 completed NCT01347944
MORE - Monitoring Revlimid - Collecting of Patient Information From Myelodysplastic Syndrome (MDS) Italian National Registry Not Available Not Available completed NCT01748240
Addition of Vorinostat to Azacitidine in Higher Risk MDS a Phase II add-on Study in Patients With Azacitidine Failure treatment 2 terminated NCT01099267
Multi-center, Survival Data Collection in Subjects Previously Enrolled in Celgene Protocol CC-5013-MDS-003 No drug interventions Not Available Not Available completed NCT01751867
An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic Syndrome treatment 3 completed NCT00908167
Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies treatment 1 completed NCT03495167
Study of SyB C-1101 in Patients With Myelodysplastic Syndrome No drug interventions treatment 1 completed NCT01068301
A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation treatment 1 completed NCT01624701
Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells No drug interventions treatment 1 / 2 terminated NCT02129101
Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies treatment 1 completed NCT02566304
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies treatment 2 active_not_recruiting NCT03150004
Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) treatment 2 recruiting NCT00271804
Study of Velcade and Thalidomide in Patients With Myelodysplasia treatment 1 terminated NCT05139004
90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome treatment 1 recruiting NCT02756572
Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms treatment 2 completed NCT00360672
Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome treatment 2 completed NCT04278768
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) treatment 1 / 2 recruiting NCT06510868
Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy No drug interventions Not Available Not Available not_yet_recruiting NCT02424968
CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma treatment 2 completed NCT01643668
Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation treatment 2 completed NCT00520468
Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS treatment 2 completed NCT03941769
2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II supportive_care 1 / 2 completed NCT02487069
Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy treatment Not Available completed NCT00819546
RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS treatment 1 active_not_recruiting NCT02452346
Study of Clinical Efficacy and Safety of Tosedostat in MDS treatment 2 completed NCT01041846
A Study for Dacogen Treatment in Patients With Myelodysplastic Syndrome No drug interventions Not Available Not Available completed NCT00525746
Molecular Epidemiology of Therapy-related Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS) No drug interventions Not Available Not Available active_not_recruiting NCT00113646
Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies treatment 2 terminated NCT01152346
Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients Not Available 1 completed NCT01828346
Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy treatment 1 / 2 completed NCT02960646
Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies treatment 1 completed NCT01336712
Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases No drug interventions treatment 2 completed NCT00723112
The Role of Erythropoietin in Myelodysplastic Syndrome No drug interventions Not Available Not Available completed NCT00226512
To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning treatment 3 withdrawn NCT03195010
Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia No drug interventions supportive_care 2 terminated NCT02221310
Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS treatment 2 completed NCT00414310
Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) treatment 2 completed NCT00569010
Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS) treatment 1 / 2 completed NCT01474681
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies treatment 1 / 2 completed NCT01652781
5 Day Versus 7 Day Azacitidine in Lower Risk Myelodysplastic Syndrome treatment 2 unknown_status NCT06543381
Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant treatment 1 recruiting NCT02190695
Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS treatment 2 completed NCT00539695
Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD treatment 2 completed NCT02683395
A Study of PLX51107 in Advanced Malignancies treatment 1 terminated NCT02566395
Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies treatment 3 completed NCT01566695
The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS) treatment 3 completed NCT02115295
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia treatment 2 recruiting NCT01178814
Revlimid in Transfusion Dependent Patients treatment 2 completed NCT00469014
Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia treatment 2 completed NCT00790855
Bendamustine in Acute Leukemia and MDS treatment 1 / 2 terminated NCT01760655
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies treatment 2 completed NCT01200355
Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome treatment 4 completed NCT01684150
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving treatment 1 completed NCT02728050
Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome treatment 1 / 2 completed NCT02083250
Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant treatment 1 completed NCT04900350
A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome treatment 1 / 2 recruiting NCT01039350
Prospective, Multicenter, Open Label and Single-arm Study of Darbepoetin Alfa for Anemia in Myelodisplastic Syndrome Patients. treatment 2 terminated NCT00687323
Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052) treatment 2 completed NCT00621023
Cephalon Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndrome treatment 2 completed NCT00533923
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders treatment 2 completed NCT01385423
Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML) treatment 1 completed NCT00867308
Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia treatment 2 terminated NCT00885508
A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q treatment 2 unknown_status NCT04493138
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations treatment 1 / 2 recruiting NCT01085838
Erlotinib in Higher Risk Myelodysplastic Syndrome treatment 1 / 2 completed NCT00003838
Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow treatment 2 completed NCT04262843
Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia treatment 2 recruiting NCT01643603
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies treatment 1 terminated NCT02727803
Personalized NK Cell Therapy in CBT treatment 2 recruiting NCT01873703
Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome treatment 2 completed NCT00796003
A Study of JNJ-30979754 (Decitabine) in Patients With Myelodysplastic Syndrome treatment 1 completed NCT00892190
Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome treatment 1 completed NCT05564390
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) screening 2 recruiting NCT00422890
Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®) No drug interventions treatment 3 completed NCT00300664
A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients. Not Available 2 / 3 completed NCT03326921
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant treatment 1 suspended NCT02312102
Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation treatment 1 active_not_recruiting NCT03739502
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant No drug interventions treatment 2 recruiting NCT06265584
Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant treatment 2 not_yet_recruiting NCT00466115
A Phase II Study of MS-275, in Combination With GM-CSF Treating Relapsed and Refractory Myeloid Malignancies treatment 2 unknown_status NCT00475384
Haploidentical Transplantation in Patients With Acute Leukemia and Myelodysplasia treatment 1 completed NCT00977782
Open-label Multicenter Study of PKC412 in Pts With AML and MDS With Either Wild-type or Mutated FLT3 treatment 1 / 2 completed NCT01575691
Phase I 5-Azacytidine Plus VPA Plus ATRA treatment 1 completed NCT01908387
Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms treatment 1 terminated NCT04191187
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies treatment 2 active_not_recruiting NCT00003687
Treatment for Chronic Pain in Patients With Advanced Cancer supportive_care 3 completed NCT00053287
Fludarabine/Carboplatin/Topotecan w/Thalidomide for Relapsed/Refractory AML, CML and MDS treatment 2 completed NCT00102687
Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes treatment 2 completed NCT00365287
Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer treatment 1 / 2 completed NCT00003887
Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation No drug interventions treatment 2 completed NCT04902833
Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms No drug interventions Not Available Not Available recruiting NCT06020833
A Single-arm Trial of Roxadustat Combined With Retinoic Acid in the Treatment of Refractory Low-risk MDS treatment 1 / 2 not_yet_recruiting NCT00044954
Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer treatment 2 completed NCT00005854
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer treatment 2 completed NCT00107354
Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant treatment 1 completed NCT00082654
Study of the Emotional Needs of Caregivers of Stem Cell Transplantation Patients No drug interventions Not Available Not Available completed NCT00015951
Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers treatment 2 completed NCT00899951
Studying Fentanyl in Patients With Cancer Not Available Not Available terminated NCT00008151
Gemtuzumab Ozogamicin, Fludarabine, and Total-body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome treatment 2 completed NCT02891551
An Observational Post Authorisation Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the Netherlands No drug interventions Not Available Not Available completed NCT00301951
Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer treatment 1 completed NCT05204953
Mean Platelet Volume and Its Relation to Risk Stratification of Myelodysplastic Syndromes No drug interventions Not Available Not Available completed NCT00380653
Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes treatment 1 completed NCT01488253
Sirolimus/Tacrolimus Combination After HLA Matched Related Peripheral Blood Stem Cell Transplants prevention 2 terminated NCT00425477
Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia treatment 2 completed NCT03176277
A Study of ONO-7475 in Patients With Acute Leukemias treatment 1 / 2 terminated NCT02779777
Tipifarnib in Subjects With Myelodysplastic Syndromes treatment 2 terminated NCT00126477
Quality of Life of Adult Cancer Survivors Who Have Undergone a Previous Bone Marrow or Peripheral Stem Cell Transplant for a Childhood Hematologic Cancer No drug interventions Not Available Not Available completed NCT02610777
An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) treatment 2 completed NCT00144677
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation prevention 2 completed NCT05392647
Hetrombopag for Lower-risk MDS With Thrombocytopenia: a Prospective，Open-label, Single-arm Study. treatment 2 not_yet_recruiting NCT00398047
Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes No drug interventions treatment 2 terminated NCT00004047
Chemotherapy in Treating Patients Who Have Hematologic Cancer treatment 1 completed NCT03885947
VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies treatment 1 completed NCT06502145
Iadademstat With Hypomethylating Agent in Patients With Myelodysplastic Syndrome treatment 1 not_yet_recruiting NCT03655145
HLA 10/10 Matched Unrelated Donor vs Haploidentical Allogenic Hematopoietic Stem Cell Transplantation No drug interventions treatment 3 unknown_status NCT00875745
Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) treatment 1 completed NCT00916045
Pilot Study of Unrelated Cord Blood Transplantation treatment 2 terminated NCT06235398
Upfront Related Donor Transplantation in Patients With Myelodisplatic Syndrome : a Phase 2 Trial No drug interventions treatment 2 not_yet_recruiting NCT00003398
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer treatment 4 completed NCT00005598
Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome treatment 2 completed NCT05805605
Allo HSCT Using RIC and PTCy for Hematological Diseases treatment 2 recruiting NCT00003805
Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count supportive_care 3 completed NCT04543305
A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies No drug interventions treatment 1 completed NCT00411905
Bortezomib and Low Dose Cytarabine in the Treatment of High-Risk Myelodysplastic Syndromes treatment 1 / 2 unknown_status NCT00045305
Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes treatment 2 completed NCT00005805
St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer No drug interventions supportive_care 3 completed NCT03814005
A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems other 1 completed NCT05031897
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant treatment 2 recruiting NCT00003997
6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous Leukemia treatment 1 completed NCT00005797
Bone Marrow Transplant in Treating Patients With Hematologic Cancers treatment 2 completed NCT00451997
Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes treatment 2 completed NCT04245397
Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome treatment 1 recruiting NCT00098683
Amifostine in Treating Young Patients With Newly Diagnosed De Novo Myelodysplastic Syndromes treatment 2 completed NCT01011283
To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS. treatment 4 terminated NCT00450983
Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases treatment 2 terminated NCT00946283
Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome No drug interventions supportive_care Not Available terminated NCT04167683
Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant No drug interventions Not Available Not Available recruiting NCT04331483
A Study to Assess a Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Allografts No drug interventions supportive_care Not Available withdrawn NCT02268383
Extension Study to Evaluate Long-Term Effects of Luspatercept in Patients With Myelodysplastic Syndromes (MDS) (A536-05/MK-6143-003) treatment 2 completed NCT00111683
MK0457 in Patients With Leukemia (0457-003) No drug interventions treatment 1 completed NCT05367583
Cohort Study Assessing the Treatment Strategy for High-Risk Myelodysplastic Syndromes in Patients Under 70 No drug interventions Not Available Not Available active_not_recruiting NCT03927261
PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS treatment 1 active_not_recruiting NCT00003661
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer treatment 2 completed NCT00003361
Decitabine in Treating Patients With Myelodysplastic Syndrome treatment 2 completed NCT03223961
A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS treatment 3 unknown_status NCT00818961
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer treatment 2 terminated NCT05732961
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms treatment 2 recruiting NCT02598661
Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) treatment 2 / 3 active_not_recruiting NCT03660228
Peri-Transfusion QOL Assessments (PTQA): A New Paradigm of Transfusion Decision Support for Patients With MDS No drug interventions health_services_research Not Available completed NCT00731328
Donor Stem Cell Transplant After Busulfan, Fludarabine, Methylprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure Syndrome No drug interventions treatment 2 completed NCT00356928
Cyclophosphamide Plus T-Cell Transplantation for Patients With Hematologic Malignancies treatment 1 terminated NCT00676728
A Study of the Histone-deacetylase Inhibitor JNJ-26481585 in Patients With Advanced or Refractory Leukemia or Myelodysplastic Syndrome treatment 1 terminated NCT01390311
Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell Transplant treatment 1 completed NCT03393611
CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome treatment 1 completed NCT05140811
A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome treatment 1 / 2 recruiting NCT03929211
CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome treatment 1 / 2 withdrawn NCT01201811
Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) treatment 4 completed NCT00915811
Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Utilising Conditioning With Fludarabine, Busulphan and Thymoglobulin treatment 2 terminated NCT00064311
Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation supportive_care 1 / 2 completed NCT04631211
Thrombosomes® in Bleeding Thrombocytopenic Patients Study treatment 2 terminated NCT04810611
Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS treatment 1 terminated NCT00109993
Campath-1H + FK506 and Methylprednisolone for GVHD supportive_care 2 completed NCT00003593
Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome treatment 3 completed NCT06303193
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms treatment 1 / 2 not_yet_recruiting NCT00602693
T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer treatment 1 completed NCT00003793
Genetic Study of Children With Soft Tissue Sarcoma or Rhabdomyosarcoma No drug interventions Not Available Not Available completed NCT05823571
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients treatment 1 recruiting NCT02164071
Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies No drug interventions Not Available Not Available completed NCT00295971
Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency Disease treatment 1 completed NCT00202371
Transfusion Effects in Myelodysplastic Patients: Limiting Exposure No drug interventions treatment 4 withdrawn NCT03113071
Safety and Activity of Digoxin With Decitabine in Adult AML and MDS treatment 1 / 2 terminated NCT02181478
Intra-Osseous Co-Transplant of UCB and hMSC treatment 0 completed NCT03175978
IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome treatment 1 / 2 terminated NCT02477878
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant treatment 1 active_not_recruiting NCT01288378
Empirical Versus Preemptive Antifungal Therapy supportive_care 3 completed NCT00005988
Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy treatment 1 completed NCT02370888
Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease treatment 1 terminated NCT00003107
Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors treatment 1 completed NCT00117507
Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients treatment 4 completed NCT03852407
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning treatment 2 recruiting NCT00008307
Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders treatment 2 unknown_status NCT03412409
RIC Regimen for Elderly or High Comorbidity Burden Patients Receiving Haplo-HSCT treatment 2 recruiting NCT06315309
Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant treatment 2 not_yet_recruiting NCT00750009
Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial No drug interventions other 3 completed NCT04044209
A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS treatment 2 withdrawn NCT04156256
CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies No drug interventions treatment 0 unknown_status NCT05088356
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft treatment 1 recruiting NCT00789256
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS treatment Not Available completed NCT05883956
A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia treatment 3 active_not_recruiting NCT00065156
Lenalidomide Safety/Efficacy in Myelodysplastic Syndromes (MDS) Associated With a Deletion (Del)(5q) Cytogenetic Abnormality treatment 2 completed NCT02320656
Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015 No drug interventions basic_science Not Available unknown_status NCT00384956
A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes treatment 2 completed NCT04866056
Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. treatment 1 / 2 terminated NCT05593185
Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS Not Available Not Available available NCT01674985
Microtransplantation With Decitabine and Cytarabine Improves Patient Outcomes in Myelodysplastic Syndromes No drug interventions treatment 1 / 2 completed NCT00952185
Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers No drug interventions supportive_care Not Available terminated NCT02867085
Study Investigating the Interactions of Bone and Hematopoiesis in the Elderly No drug interventions Not Available Not Available unknown_status NCT00003885
Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma treatment 2 unknown_status NCT02921815
A Study to Analyze the Occurrence of Transformation From Myelodysplastic Syndrome to Acute Myeloid Leukemia in Patients With Myelodysplastic Syndrome Who Received Revlimid® 5 mg Capsules and Who Are Continuing or no Longer Continuing Revlimid Treatment No drug interventions Not Available Not Available completed NCT00544115
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders treatment 2 active_not_recruiting NCT06144515
Collection of Samples of Bone Marrow Aspiration From Patients With Myelodysplastic Syndrome No drug interventions Not Available Not Available recruiting NCT00691015
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant supportive_care 2 completed NCT01484015
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia treatment 1 completed NCT02117115
Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation screening 0 completed NCT00003415
Amifostine Plus Topotecan in Treating Patients With Myelodysplastic Syndrome treatment 1 / 2 completed NCT05086315
First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) No drug interventions treatment 1 / 2 recruiting NCT00089037
Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation supportive_care 1 / 2 completed NCT03696537
IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT treatment 1 terminated NCT00245037
Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer treatment 1 / 2 completed NCT01928537
Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine treatment 3 completed NCT01546337
Search for Predictive Markers of Efficacy of ESAs in Patients With Non-myeloid Malignancies or Myelodysplastic Syndrome No drug interventions Not Available Not Available terminated NCT00346632
An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia No drug interventions treatment 1 terminated NCT00531232
A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS) treatment 2 completed NCT00479232
Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1) treatment 1 completed NCT00004232
Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer supportive_care 1 completed NCT00052832
Doxercalciferol in Treating Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia No drug interventions treatment 2 completed NCT00002832
Decitabine and Peripheral Stem Cell Transplantation in Treating Patients Who Have Relapsed Following Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia treatment 1 / 2 completed NCT00005852
Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant treatment 2 terminated NCT02223052
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies treatment 1 completed NCT05583552
Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy treatment 2 recruiting NCT02294552
Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT treatment 2 completed NCT00002800
Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome treatment 2 completed NCT00234000
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes treatment 1 terminated NCT05924100
Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TD treatment 2 recruiting NCT06021600
A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine treatment 1 recruiting NCT05641259
A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML treatment 1 recruiting NCT02907359
Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs treatment 3 completed NCT03258359
Personalized Adoptive Cellular Therapy Targeting MDS Stem Cell Neoantigens (PACTN) No drug interventions treatment 1 unknown_status NCT00346359
Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer treatment 2 completed NCT03579875
Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders treatment 2 recruiting NCT00104975
Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer treatment 1 completed NCT03946670
A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS). treatment 2 completed NCT05933070
A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML No drug interventions treatment 1 terminated NCT02508870
A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes treatment 1 completed NCT05120570
PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation No drug interventions supportive_care 1 / 2 recruiting NCT00499070
Assessing Immune Function in Young Patients With Cytopenia That Did Not Respond to Treatment No drug interventions Not Available Not Available completed NCT05178342
Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948 treatment 2 terminated NCT00006042
Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer treatment 1 completed NCT00002742
Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer supportive_care 3 completed NCT03363399
Flow Cytometric Analysis of Peripheral Blood Neutrophil Myeloperoxidase Expression and Myelodysplastic Syndromes No drug interventions Not Available Not Available completed NCT05607199
A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics treatment 1 recruiting NCT06439199
Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive Chemotherapy No drug interventions Not Available Not Available not_yet_recruiting NCT01747499
Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation treatment 1 / 2 terminated NCT00004899
Chemotherapy Plus Bone Marrow Transplantation and Filgrastim in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome treatment 2 completed NCT03016806
Umbilical Cord Blood Transplantation From Unrelated Donors treatment 1 recruiting NCT00104806
Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes treatment 2 terminated NCT04264806
A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT) treatment 2 withdrawn NCT00900406
Collecting and Storing Tissue and DNA Samples From Patients Undergoing a Donor Stem Cell Transplant No drug interventions Not Available Not Available completed NCT03964506
Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant No drug interventions treatment 0 recruiting NCT04419649
A Study of KER-050 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes No drug interventions treatment 2 recruiting NCT03594149
Efficiency of Antibacterial Prophylaxis in Azacitidine Treated Patients prevention 3 unknown_status NCT03588936
Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant treatment 1 terminated NCT00719836
A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies treatment 1 / 2 completed NCT02564536
Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) treatment 1 withdrawn NCT03682536
A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve treatment 3 active_not_recruiting NCT00004036
Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer supportive_care 1 unknown_status NCT00003436
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia treatment 3 completed NCT01118013
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant treatment 2 terminated NCT00003913
Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Nonmalignant Hematologic Disease treatment 2 completed NCT00816413
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer treatment 1 / 2 withdrawn NCT05931718
Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia Not Available Not Available recruiting NCT00002718
T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia treatment 2 completed NCT00304018
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer treatment 1 completed NCT04399018
Development and Prospective Validation of a Standardized Flow Cytometric Assay of Peripheral Blood Neutrophil Myeloperoxidase Expression for Ruling Out Myelodysplastic Syndromes. No drug interventions Not Available Not Available active_not_recruiting NCT01158118
Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors treatment 2 completed NCT03310918
A Collaborative Palliative and Leukemia Care Model for Patients With AML and MDS Receiving Non-Intensive Therapy No drug interventions supportive_care Not Available recruiting NCT04827719
BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS treatment 2 active_not_recruiting NCT00006019
Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer treatment 2 completed NCT00303719
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy treatment 2 terminated NCT00376519
Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases treatment 1 terminated NCT02928419
Efficacy of Eltrombopag Plus Lenalidomide Combination Therapy in Patients With IPSS Low and Intermediate-risk Myelodysplastic Syndrome With Isolated del5q treatment 2 terminated NCT03961919
Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant treatment 2 completed NCT00003619
Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia treatment 1 / 2 completed NCT04402541
Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome No drug interventions treatment 1 completed NCT04888741
Methods of T Cell Depletion Trial (MoTD) prevention 2 recruiting NCT06050941
Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS treatment 2 not_yet_recruiting NCT06297941
Study of REM-422 in Patients With AML or Higher Risk MDS treatment 1 recruiting NCT03746041
A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes treatment 1 completed NCT00844441
Early Discharge and Outpatient Care After Chemotherapy in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia No drug interventions health_services_research Not Available completed NCT03621241
Immunophenotyping of Blood Cells in the Diagnosis Work-up of Myelodysplastic Syndromes No drug interventions Not Available Not Available recruiting NCT00005641
Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation treatment 2 terminated NCT00134017
Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer treatment 2 completed NCT00608517
Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil treatment Not Available terminated NCT04256317
A Study of ASTX030 (Cedazuridine in Combination With Azacitidine) in MDS, CMML, or AML treatment 2 / 3 recruiting NCT00301834
Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders treatment 2 completed NCT03011034
Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment treatment 2 completed NCT04968834
Protocol For Genomically Profiling, Collecting, Archiving And Distributing Blood And Bone Marrow Specimens From Children And Young Adults With Hematologic Malignancy No drug interventions Not Available Not Available recruiting NCT02243124
A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS) treatment 1 terminated NCT00324324
Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant supportive_care 3 terminated NCT06069024
Population Pharmacokinetic Study Based on Quantitative Pharmacology in Patients With Lenalidomide No drug interventions Not Available Not Available completed NCT04823624
MBG453 in Lower Risk MDS treatment 2 recruiting NCT00003816
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer treatment 2 / 3 completed NCT05902416
Clinical Registration Study of Haplo-HSCT for Elderly Patients With Acute Leukemia/ Myelodysplastic Syndrome No drug interventions Not Available Not Available recruiting NCT02038816
Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS) treatment 2 terminated NCT00077116
Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome treatment 2 completed NCT00008216
Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer No drug interventions Not Available Not Available terminated NCT03842696
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation prevention 1 / 2 recruiting NCT00185796
TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD No drug interventions treatment 2 completed NCT01165996
Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome treatment 1 / 2 completed NCT00003396
Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer treatment 2 completed NCT00374296
MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease treatment 2 terminated NCT00004896
Busulfan and Cyclophosphamide Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome treatment 2 completed NCT00361296
Vaccine Therapy in Treating Patients With Myelodysplastic Syndromes No drug interventions treatment 0 terminated NCT00241358
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies treatment 1 / 2 completed NCT00004058
12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder treatment 1 terminated NCT00077558
3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome treatment 1 completed NCT05066958
Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT No drug interventions prevention 1 / 2 unknown_status NCT00438958
Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases treatment 3 completed NCT02661035
Allo HSCT Using RIC for Hematological Diseases treatment 2 completed NCT03184935
Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-MDS) in the Treatment of Myelodysplastic Syndrome (MDS) treatment 1 / 2 suspended NCT01164163
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease treatment 1 completed NCT01364363
Unrelated Donor Stem Cell Transplantation No drug interventions treatment Not Available completed NCT00589563
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer supportive_care 2 completed NCT00004263
Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic Syndrome treatment 1 completed NCT03813186
Effect of Food on Blood Levels of ASTX727 basic_science 1 completed NCT02428686
Treatment of Anemia With Epoetin Beta in Low Risk Myelodysplastic Syndrome (MDS) treatment 2 completed NCT03558386
Study of Quality of Life in Older vs. Younger Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes No drug interventions Not Available Not Available completed NCT01890486
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen No drug interventions Not Available Not Available recruiting NCT00217386
Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic Syndromes treatment 2 completed NCT00049686
VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome treatment 1 completed NCT02074839
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation treatment 1 recruiting NCT03612739
EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2 treatment 1 withdrawn NCT00004239
506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment treatment 1 terminated NCT00761722
Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma treatment 1 completed NCT05400122
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer treatment 1 recruiting NCT05970822
Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML treatment 1 recruiting NCT00376922
Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other Diseases No drug interventions supportive_care Not Available completed NCT02689622
PREDICTive FactOR of Overall Survival Among Geriatric Assessment Tools and Disease Related Factors in Elderly Patients With High Risk Myelodysplastic Syndromes. No drug interventions other Not Available completed NCT01137825
Registry of Older Patients With Cancer No drug interventions Not Available Not Available recruiting NCT00919425
S9910, Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer No drug interventions Not Available Not Available completed NCT00080925
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies treatment 1 completed NCT00641030
Clofarabine and High-Dose Melphalan Followed by Donor Stem Cell Transplant in Patients With Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Myelodysplastic Syndromes treatment 1 completed NCT04629430
Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT No drug interventions treatment Not Available completed NCT00803530
Study of Association of Arsenic Trioxide (ATO) and Ascorbic Acid in Myelodysplastic Syndromes treatment 2 terminated NCT00521430
Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease treatment Not Available completed NCT03434730
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation treatment 2 active_not_recruiting NCT00046930
Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia treatment 3 completed NCT05298930
Feasibility Study to Assess an Adapted Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Transplantation No drug interventions supportive_care Not Available completed NCT04942730
Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe) treatment 2 completed NCT00555048
Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer treatment 1 / 2 terminated NCT01571648
A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of Oral Azacitidine in Japanese Patients With Myelodysplastic Syndromes treatment 1 completed NCT00022048
Bevacizumab in Treating Patients With Myelodysplastic Syndrome treatment 1 / 2 completed NCT00001748
HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies No drug interventions treatment 1 completed NCT04036448
A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in Korea Not Available Not Available completed NCT00006348
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment supportive_care 3 completed NCT03164057
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia treatment 2 active_not_recruiting NCT04943757
Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies treatment 2 recruiting NCT00448357
Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen treatment 1 / 2 completed NCT04370457
MyPal ePRO-based Early Palliative Care System in Adult Patients With Hematologic Malignancies No drug interventions supportive_care Not Available unknown_status NCT01211457
Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) treatment 1 / 2 unknown_status NCT06146257
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes No drug interventions treatment 1 recruiting NCT02145026
A Study of Epoetin Beta Treatment in Anemic Participants With Myelodysplastic Syndrome (MDS) treatment 4 completed NCT06098326
CyFluATG in Lower Risk MDS treatment 2 active_not_recruiting NCT00118326
Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous Disease treatment 1 / 2 completed NCT05601726
First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients No drug interventions treatment 1 active_not_recruiting NCT00423826
Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease Not Available Not Available no_longer_available NCT04628026
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 treatment 3 recruiting NCT00002926
Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia treatment 3 unknown_status NCT04609826
A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) No drug interventions treatment 1 active_not_recruiting NCT05201066
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. treatment 2 recruiting NCT03412266
RIC Regimen for Low- and Intermediate-risk MDS Receiving Haplo-HSCT treatment 2 unknown_status NCT00544466
Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies treatment 1 / 2 active_not_recruiting NCT00005866
S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia treatment 3 completed NCT06462365
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) No drug interventions prevention 1 recruiting NCT04485065
Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS treatment 1 suspended NCT00899665
Proteases in Patients With Prostate Cancer That Has Spread to the Bone No drug interventions Not Available Not Available completed NCT06004765
Efficacy and Safety of Lenalidomide Combined With Azacitidine vs Azacitidine in the Treatment of MDS-RS treatment 4 not_yet_recruiting NCT00418665
A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid supportive_care 2 completed NCT02498665
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies treatment 1 completed NCT03452774
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry No drug interventions Not Available Not Available recruiting NCT00074074
Infliximab in Treating Patients With Myelodysplastic Syndrome treatment 2 completed NCT06206174
TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies No drug interventions treatment 1 / 2 recruiting NCT00064974
Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes treatment 2 completed NCT00900120
Collecting and Storing Blood Samples From Patients With Cancer No drug interventions Not Available Not Available withdrawn NCT00486720
Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064) treatment 2 terminated NCT04003220
Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker No drug interventions Not Available Not Available recruiting NCT03598582
Biological Predictive Factors of Response to ESA in Low Risk MDS Patients treatment 4 completed NCT01904682
Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs treatment 2 completed NCT01045382
MSC and HSC Coinfusion in Mismatched Minitransplants No drug interventions treatment 2 terminated NCT00014482
Music Therapy to Ease Pain and Emotional Distress in Patients With Hematologic Cancer Who Are Undergoing High-Dose Therapy and Stem Cell Transplantation No drug interventions Not Available Not Available completed NCT00003082
Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer No drug interventions treatment 1 completed NCT00062231
Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With Cancer supportive_care Not Available terminated NCT06337331
Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant treatment 2 withdrawn NCT06529731
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation treatment 2 recruiting NCT01081431
Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5q treatment 2 completed NCT06244173
Clinical and Laboratory Parameters of Myelodysplastic Syndromes at Upper Egypt No drug interventions Not Available Not Available completed NCT00481273
AVIDA The Vidaza® (Azacitidine) Patient Registry Not Available Not Available completed NCT02942173
CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT No drug interventions prevention 2 / 3 completed NCT00439673
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS treatment 2 completed NCT04602273
Treatment of High Risk Myelodysplastic Syndromes (MDS) Not Candidates for Allogeneic Transplantation of Hematopoietic Progenitors (ALO-HSCT) Not Available Not Available unknown_status NCT03107273
Development of an in Vitro Hematopoietic Culture System and Application to Myelodysplastic Syndromes. No drug interventions Not Available Not Available completed NCT00916227
A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome treatment 1 completed NCT00899327
Biomarkers in Patients at Risk of Developing Myelodysplastic Syndrome or Other Disorders and in Healthy Participants No drug interventions Not Available Not Available unknown_status NCT04745676
A Telehealth Advance Care Planning Intervention for Older Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome No drug interventions supportive_care Not Available active_not_recruiting NCT00064376
Paricalcitol in Treating Patients With Myelodysplastic Syndrome treatment 2 completed NCT01026376
An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS) Not Available Not Available no_longer_available NCT00003960
Donor Bone Marrow Transplantation in Treating Patients With Hematologic Cancer treatment 2 completed NCT00469560
Safety, Tolerability, and Efficacy of Deferasirox in MDS treatment 3 completed NCT01324960
Azacitidine With or Without Ceplene/Interleukin-2 in Patients With Higher Risk Myelodysplastic Syndromes treatment 1 / 2 withdrawn NCT00027560
Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer treatment 2 completed NCT05455294
Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms treatment 1 active_not_recruiting NCT00324194
A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes treatment 1 completed NCT06279494
Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors prevention 1 / 2 not_yet_recruiting NCT02835794
A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS) treatment 1 / 2 withdrawn NCT00217594
A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome treatment 2 completed NCT00000591
T-Cell Depletion in Unrelated Donor Marrow Transplantation No drug interventions treatment 3 completed NCT02472691
Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT treatment 2 completed NCT01822691
Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS) treatment 2 completed NCT06299462
PTCy and ATG for MSD and MUD Transplants prevention 1 / 2 recruiting NCT00025662
Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS No drug interventions treatment 2 completed NCT00725062
Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant No drug interventions treatment 1 terminated NCT00295880
Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer No drug interventions treatment 1 / 2 terminated NCT02969980
Hematopoietic Cell Transplantation With Post-transplantation Cyclophosphamide in MDS treatment 2 completed NCT03140280
Hypomethylating Properties of Freeze-dried Black Raspberries (BRB) in Patients With Myelodysplastic Syndrome or Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) No drug interventions treatment 2 completed NCT00148980
Creation of Bone Marrow Microenvironment for Treatment of Myelodysplastic Syndrome (MDS) in Conjunction With Allogeneic Stem Cell Transplantation No drug interventions Not Available 2 withdrawn NCT03275480
Institut Paoli Calmettes Myelodysplastic Syndromes Database No drug interventions Not Available Not Available recruiting NCT02493829
B7.1/IL-2 Leukaemia Cell Vaccine for Non-Transplant AML RFUSIN2-AML2 (NTX) No drug interventions treatment 1 unknown_status NCT00324129
A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic Syndromes treatment 1 completed NCT05515029
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis treatment 3 active_not_recruiting NCT04889729
GENOMED4ALL: Improving MDS Classification and Prognosis by AI No drug interventions Not Available Not Available active_not_recruiting NCT00469729
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy treatment 2 / 3 completed NCT00424229
Lenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31] treatment 2 unknown_status NCT00002989
Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome treatment 3 unknown_status NCT04428489
Follow-up Study of ICUS and CCUS Patients No drug interventions Not Available Not Available enrolling_by_invitation NCT00510289
Sorafenib in Myelodysplastic Syndrome treatment 2 terminated NCT01809392
Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome treatment 2 / 3 unknown_status NCT00069992
Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML treatment 2 terminated NCT00005092
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer treatment 1 completed NCT01957644
Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML treatment 1 terminated NCT00838240
Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia treatment 1 / 2 unknown_status NCT00914940
Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD treatment 2 terminated NCT00006040
Radiolabeled Monoclonal Antibody Therapy and Etoposide Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Myelodysplastic Syndrome or Refractory Leukemia treatment 1 completed NCT05986240
Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML treatment 1 recruiting NCT00035867
Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome treatment 1 / 2 completed NCT00806767
Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer treatment 2 completed NCT06091267
PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes treatment 1 / 2 recruiting NCT03734601
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation treatment 2 completed NCT05367401
A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants treatment 1 / 2 withdrawn NCT02848001
A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes treatment 1 terminated NCT03027401
Clinical Sequencing of Cancer and Tissue Repository: OncoGenomics No drug interventions Not Available Not Available withdrawn NCT04266301
Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) treatment 3 active_not_recruiting NCT00281801
Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow Transplantation No drug interventions Not Available Not Available completed NCT00134004
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer treatment 2 completed NCT03151304
A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes treatment 2 terminated NCT00005804
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer treatment 2 completed NCT00002504
Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer treatment 2 completed NCT02909972
Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome treatment 1 completed NCT00354172
Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers. treatment 2 terminated NCT03301168
Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant treatment 1 / 2 active_not_recruiting NCT00812968
Study of CC-5013 to Evaluate Safety, Pharmacokinetics and Effectiveness for Japanese Patients With Symptomatic Anemia Associated With Myelodysplastic Syndrome With a Del(5)(q31-33) Abnormality. treatment 2 completed NCT00900068
Blood Samples From Patients on a Clinical Trial to CINV During HSCT No drug interventions Not Available Not Available terminated NCT03232268
HLA-mismatched Microtransplantation Without Immunosuppressive Treatment in Patients With Myeloid Hemopathies No drug interventions treatment 1 recruiting NCT02335268
Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk MDS and Thrombocytopenia treatment 2 completed NCT05937568
Expanded Access for Treatment With Imetelstat Not Available Not Available approved_for_marketing NCT04226768
Enhanced Palliative Care in MDS and AML No drug interventions supportive_care Not Available active_not_recruiting NCT00020969
Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes treatment 2 terminated NCT00030069
Calcitriol and Dexamethasone in Patients With Myelodysplastic Syndromes treatment 2 completed NCT00072969
A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS) treatment 2 completed NCT00014469
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer treatment 2 completed NCT05490446
A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS) treatment 2 active_not_recruiting NCT03030612
A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS) treatment 1 / 2 completed NCT00301912
Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer treatment 2 withdrawn NCT03045510
Efficacy and Safety of Ultra Small Dose Decitabine for the Lower Risk MDS Patients With Transfusion Dependent treatment 2 unknown_status NCT04953910
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment treatment 1 recruiting NCT00455910
Thalidomide at Low Dose for the Treatment of Patient With Myelodysplastic Syndromes - THAL-SMD-200 treatment 2 completed NCT05800210
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases No drug interventions treatment 2 recruiting NCT00075010
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes treatment 1 / 2 completed NCT05457010
Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS No drug interventions treatment 1 recruiting NCT00255710
Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer supportive_care 1 completed NCT03408210
Total Marrow and Lymphoid Irradiation and Chemotherapy for Myelodysplastic Syndrome or Acute Leukemia No drug interventions treatment Not Available unknown_status NCT00274781
Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes treatment 2 completed NCT04263181
AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration No drug interventions Not Available Not Available recruiting NCT00003681
Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome treatment 2 unknown_status NCT00061581
Experimental Bone Marrow Transplant Protocol No drug interventions treatment 2 completed NCT03802695
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies No drug interventions treatment 1 recruiting NCT00084695
Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases treatment 2 unknown_status NCT00014495
Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer treatment 1 / 2 completed NCT01595295
Registry on Hypomethylating Agents in Myeloid Neoplasms No drug interventions Not Available Not Available completed NCT04522895
IDH2-Post-Allo-Trial for Patients With IDH2-mut Myeloid Neoplasms After Allo-SCT treatment 2 active_not_recruiting NCT01496495
A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes treatment 1 completed NCT00004114
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer treatment 1 withdrawn NCT03755414
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation treatment 1 completed NCT00413114
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)for the Treatment of Myelodysplastic Syndromes (MDS) treatment 2 completed NCT04328714
Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease treatment 1 suspended NCT03121014
Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes treatment 2 active_not_recruiting NCT00004255
Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation treatment 2 / 3 completed NCT05918055
Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes treatment 1 / 2 recruiting NCT00081055
OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies supportive_care 2 withdrawn NCT02211755
Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors treatment 1 recruiting NCT00146055
Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood No drug interventions treatment 2 completed NCT00024050
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome treatment 2 completed NCT02435550
iCare for Cancer Patients No drug interventions diagnostic Not Available terminated NCT04477850
A Study to Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Chinese and Japanese Participants With Ring Sideroblasts Who Require Red Blood Cell Transfusions treatment 2 active_not_recruiting NCT00804050
Multicentric Study Comparison Between Erythropoietin and Erythropoietin Associated to Differentiating Therapy With Acid 13-cis-retinoic and Dihydroxyvitamin D3 in Myelodysplastic Syndromes Without Excess of Blasts No drug interventions treatment 3 terminated NCT00017550
Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome No drug interventions treatment 2 completed NCT00030550
Thalidomide in Treating Anemia in Patients With Myelodysplastic Syndrome treatment 2 completed NCT03999723
Combining Active and Passive DNA Hypomethylation No drug interventions treatment 2 recruiting NCT00296023
Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer treatment Not Available completed NCT00068523
Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies treatment Not Available completed NCT03018223
Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT prevention 1 completed NCT01744223
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant treatment 1 / 2 active_not_recruiting NCT02912208
Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes treatment 2 active_not_recruiting NCT00003408
Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer treatment 2 completed NCT05358808
ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML) treatment 2 recruiting NCT00004208
Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic Syndrome treatment 3 completed NCT02488408
A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS treatment 1 / 2 unknown_status NCT00691938
LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) treatment 1 / 2 completed NCT03446638
iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes treatment Not Available withdrawn NCT00003138
Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes treatment 3 completed NCT02875743
King's Invasive Aspergillosis Study II prevention 4 completed NCT00065143
Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome treatment 2 completed NCT00481143
Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload treatment 4 completed NCT02775903
An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML) treatment 2 completed NCT04187703
5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies treatment 0 recruiting NCT00516503
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer supportive_care 3 completed NCT00776503
Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia treatment 1 / 2 completed NCT00121303
Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes treatment 3 completed NCT00662090
Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood No drug interventions Not Available Not Available active_not_recruiting NCT00064090
3-AP and Cytarabine in Treating Patients With Hematologic Cancer treatment 1 completed NCT03057990
Pyrimethamine for Intermediate/High-risk Myelodysplastic Syndromes (MDS) treatment 1 withdrawn NCT00008164
Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia No drug interventions treatment 2 unknown_status NCT00967564
Survey on QUality of Life In myeloDisplasia (SQUID) No drug interventions Not Available Not Available completed NCT02856464
Prophylactic DLI for the Prevention of Relapse Post HSCT in Patients With High Risk Myeloid Malignancy No drug interventions treatment 2 unknown_status NCT04014764
Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy No drug interventions Not Available Not Available completed NCT00961064
A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS) treatment 2 completed NCT03306264
Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML treatment 3 completed NCT00095264
A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Syndrome treatment 2 completed NCT03572764
CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome treatment 1 active_not_recruiting NCT00179621
Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality treatment 3 completed NCT04803721
Interplay Between Immune and Metabolic Programs in Myelodysplastic Syndromes No drug interventions Not Available Not Available recruiting NCT00230321
A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS) treatment 1 / 2 completed NCT05969821
Clonal Hematopoiesis of Immunological Significance No drug interventions Not Available Not Available not_yet_recruiting NCT06113302
A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS) treatment 0 recruiting NCT00871702
Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease No drug interventions treatment 1 completed NCT02273102
Study of TCP-ATRA for Adult Patients With AML and MDS treatment 1 completed NCT00940602
Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study treatment 2 completed NCT00003602
Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia treatment 3 unknown_status NCT03454984
SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation prevention 2 unknown_status NCT02804984
Identification of Molecular Defects in Idiopathic Cytopenia of Undetermined Significance No drug interventions Not Available Not Available unknown_status NCT00034684
Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701) No drug interventions treatment 1 / 2 completed NCT06551584
Phase I Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT No drug interventions treatment 1 not_yet_recruiting NCT00987584
Phase II Cont. IV of ON 01910.Na in MDS w/ Trisomy 8/Intermed-1, 2/High Risk No drug interventions Not Available Not Available completed NCT00143884
Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood No drug interventions educational_counseling_training 2 terminated NCT02281084
Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes treatment 2 completed NCT06532084
Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen treatment 2 recruiting NCT01718379
Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality. treatment 2 completed NCT05788679
A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS treatment 2 recruiting NCT00569179
A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies No drug interventions treatment 1 terminated NCT00281879
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer treatment 2 terminated NCT00397579
DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes treatment 1 / 2 completed NCT00006379
Non-Ablative Allo HSCT For Hematologic Malignancies or SAA treatment 2 completed NCT00480987
Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS) treatment 1 / 2 terminated NCT03595787
COaching and Prehabilitation: Faisability Study in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome No drug interventions supportive_care Not Available recruiting NCT01835587
Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS). treatment 1 / 2 completed NCT06138587
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation No drug interventions treatment 1 recruiting NCT00003187
Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma treatment 2 / 3 completed NCT00083187
VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia treatment 2 completed NCT01400633
An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome Not Available Not Available completed NCT00002833
Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia treatment 2 completed NCT04053933
Observational Study Towards the Impact of Newly Started Treatment in MDS on QoL No drug interventions Not Available Not Available unknown_status NCT05588154
Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy Volunteers Used for Comparative Analysis of Myeloid Malignancies No drug interventions Not Available Not Available recruiting NCT03083054
Cellular Immunotherapy for Patients With High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia No drug interventions treatment 1 / 2 unknown_status NCT01700751
Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation treatment 1 completed NCT00003451
Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer treatment 1 completed NCT02743351
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies No drug interventions prevention 1 / 2 completed NCT00611351
Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer treatment 2 completed NCT01913951
Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes treatment 1 completed NCT00005853
Biological Therapy in Treating Patients With Myelodysplastic Syndrome treatment 2 completed NCT00055653
Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders treatment 2 completed NCT00120653
Metoclopramide to Treat Anemia in Patients With Myelodysplastic Syndrome (MDS) treatment 2 withdrawn NCT00996047
S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers No drug interventions Not Available Not Available completed NCT04174547
An European Platform for Translational Research in Myelodysplastic Syndromes No drug interventions Not Available Not Available unknown_status NCT00946647
A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). treatment 1 / 2 completed NCT00002547
Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome treatment 2 completed NCT06487247
HEME Home Transfusion Program No drug interventions supportive_care Not Available not_yet_recruiting NCT01350245
Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor treatment 2 completed NCT00004145
Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer treatment 2 completed NCT00782145
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families No drug interventions supportive_care 3 completed NCT04676945
Analysis of Risk in MDS Over Time - Comparison of Treated vs Untreated Patients No drug interventions Not Available Not Available completed NCT00619645
Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers treatment 2 completed NCT00004245
Sodium Salicylate in Treating Patients With Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Chronic Lymphocytic Leukemia treatment 1 completed NCT06379945
Unified platforM for a Better integRal Evaluation of MyeLodyspLastic Syndromes in SpAin-Strategy for Unraveling Personalized genoMic Medicine in Public heAlth System (UMBRELLA-SUMMA) No drug interventions Not Available Not Available recruiting NCT00593645
Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation treatment 2 terminated NCT05434598
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS No drug interventions diagnostic Not Available recruiting NCT02991898
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies No drug interventions treatment 2 terminated NCT05320198
Study of DISC-0974 in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia No drug interventions treatment 1 / 2 recruiting NCT00006098
PS-341 in Treating Patients With Hematologic Cancer treatment 1 completed NCT05433805
Lifestyle-modifying Interventions in Low-risk MDS Patients No drug interventions treatment Not Available not_yet_recruiting NCT05875805
A Telehealth Advance Care Planning Intervention No drug interventions supportive_care Not Available recruiting NCT06008405
Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy treatment 1 recruiting NCT02619097
Safety & Pharmacokinetics of Pegolsihematide for Treatment of Anemia Patient With Myelodysplastic Syndromes No drug interventions treatment 1 unknown_status NCT04953897
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment treatment 1 recruiting NCT00607997
Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia treatment 2 completed NCT00295997
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia treatment Not Available unknown_status NCT05194397
Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors No drug interventions treatment 2 recruiting NCT04869683
Biocollection in MyeloDysplastic Syndrome (P-MDS) No drug interventions health_services_research Not Available recruiting NCT02452983
Sertraline in Treatment of Low-Risk Myelodysplastic Syndrome treatment 1 terminated NCT00006083
Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter supportive_care 3 completed NCT05201183
A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies treatment 1 / 2 withdrawn NCT01736683
Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) treatment 2 completed NCT00010283
Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon supportive_care 1 / 2 completed NCT05150561
Muscle Dysfunction in Patients With Haematological Diseases No drug interventions Not Available Not Available unknown_status NCT00787761
Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer treatment 2 completed NCT03469661
Differential Diagnostic of Immune ThrombocytoPenia (ITP) and Myelodysplastic Syndrome (MDS) No drug interventions Not Available Not Available completed NCT02308761
A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome treatment 1 completed NCT05584761
Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML No drug interventions treatment 1 / 2 recruiting NCT00003961
Sargramostim After Bone Marrow Transplantation in Treating Patients With Myelodysplastic Syndrome treatment 2 completed NCT04024761
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation treatment 1 enrolling_by_invitation NCT01203228
Dose-reduced Versus Standard Conditioning in MDS/sAML No drug interventions treatment 3 terminated NCT00516828
Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome treatment 1 / 2 completed NCT05170828
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies treatment 1 withdrawn NCT03843528
Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation treatment 1 recruiting NCT00290628
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer treatment Not Available terminated NCT05835011
A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS) treatment 2 terminated NCT01688011
Connect® Myeloid Disease Registry Not Available Not Available recruiting NCT00700011
Clofarabine for Myelodysplastic Syndrome (MDS) Patients Who Failed Vidaza Treatment (tx) treatment 2 terminated NCT00666211
Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain No drug interventions supportive_care 3 completed NCT01519011
Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine treatment 1 completed NCT00716911
Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant supportive_care Not Available completed NCT00113893
SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes. treatment 2 completed NCT00003693
Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia treatment 1 completed NCT00406393
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) treatment 3 completed NCT00005593
Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed/Refractory Acute Leukemia or Advanced Myelodysplastic Syndrome treatment 1 completed NCT06218771
A Study of TQB3454 Tablets in Patients With Blood Tumors No drug interventions treatment 1 / 2 recruiting NCT00004871
Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome treatment 1 completed NCT00003171
Bryostatin 1 in Treating Patients With Myelodysplastic Syndrome treatment 2 completed NCT05263271
Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome treatment 1 unknown_status NCT00874978
The Efficacy and Safety of Lenalidomide Monotherapy in Red Blood Cell Transfusion Dependent Subjects With Myelodysplastic Syndrome (MDS) Associated With Del (5q) Abnormality treatment 2 completed NCT04251078
Monitoring Mutational Burden in Low Risk MDS Patients Using Sequential Peripheral Blood Samples No drug interventions Not Available Not Available unknown_status NCT04951778
Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes No drug interventions treatment 1 recruiting NCT00513578
Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome treatment 2 unknown_status NCT03187288
Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS treatment 1 completed NCT04904588
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide treatment 2 recruiting NCT00003407
Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML supportive_care 2 withdrawn NCT01036009
A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies No drug interventions treatment 2 completed NCT00588809
Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia treatment 2 completed NCT00002809
Bone Marrow Transplant Plus Cyclophosphamide and Total-Body Irradiation in Treating Patients With Hematologic Cancer treatment 2 completed NCT03503409
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome treatment 2 active_not_recruiting NCT01381809
An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes treatment 3 completed NCT05107856
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies treatment 1 terminated NCT01085656
A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS treatment 1 terminated NCT00565656
A Trial of Bevacizumab in Myelodysplastic Syndromes (Int-1, Int-2 and High Risk According to International Prognostic Scoring System (IPSS)) With Excess of Marrow Blasts treatment 2 terminated NCT04587856
Molecular Mechanisms of Disease Relapse After Allogenic Stem Cell Transplantation in MDS Patients No drug interventions basic_science Not Available recruiting NCT00019656
Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer treatment 1 completed NCT00624585
Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts treatment Not Available completed NCT04668885
CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS No drug interventions treatment 2 active_not_recruiting NCT06499285
The Efficacy and Safety of Elritercept in Adult Participants With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) With Anemia (RENEW) No drug interventions treatment 3 not_yet_recruiting NCT05745285
Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care No drug interventions supportive_care Not Available not_yet_recruiting NCT00809185
RAD001(Everolimus) in Treating Patients With Myelodysplastic Syndromes treatment 2 terminated NCT04013685
Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies No drug interventions treatment 1 active_not_recruiting NCT00317785
Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other Diseases treatment 2 completed NCT04060485
Screening Gene Mutations in Myeloid Cancers by Next Generation Sequencing to Improve Treatment Results No drug interventions Not Available Not Available recruiting NCT06001385
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis treatment 2 recruiting NCT00915785
Azacytidine for the Treatment of Myelodysplastic Syndromes/Acute Myeloid Leukemia (MDS/AML) With High Risk (Chromosome 7 and or Complex) Cytogenetic Abnormalities treatment 2 completed NCT02786485
Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT treatment 1 withdrawn NCT04893915
Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS treatment 2 withdrawn NCT03059615
A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS treatment 2 withdrawn NCT03900715
An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion treatment 2 completed NCT00242515
T-cell Depleted Donor Lymphocyte Infusion (DLI)for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS) No drug interventions treatment 1 / 2 unknown_status NCT00891137
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy supportive_care 1 completed NCT05469737
A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS) treatment 2 / 3 active_not_recruiting NCT06378437
A Study of GLB-001 in Patients With Myeloid Malignancies No drug interventions treatment 1 recruiting NCT00328237
Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation No drug interventions treatment 2 unknown_status NCT00265837
Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer No drug interventions treatment 3 completed NCT05807932
Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML treatment 1 / 2 recruiting NCT00321932
Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant treatment 2 completed NCT01116232
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation supportive_care 2 terminated NCT05245032
Biologically Focused Therapy of Treatment-Refractory MDS Patients No drug interventions Not Available Not Available active_not_recruiting NCT00100152
A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013) treatment 1 terminated NCT00253552
G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders treatment Not Available terminated NCT01015352
Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA) treatment 2 completed NCT01687400
Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes treatment 2 completed NCT04797000
Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion Dependence treatment 2 recruiting NCT01755000
Study of Hypotensive Hematopoietic Malignancy Patients' USCOM Readings No drug interventions supportive_care Not Available completed NCT00042900
Pyroxamide in Treating Patients With Advanced Cancer treatment 1 completed NCT00382200
Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes treatment 1 / 2 completed NCT06536959
VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS treatment 2 recruiting NCT03318159
Posaconazole Prophylaxis During ATG Treatment for hMDS/AA Patients prevention 2 completed NCT00003959
Vaccine Therapy in Treating Patients With Myelodysplastic Syndrome treatment 1 completed NCT00996359
Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation No drug interventions treatment 1 terminated NCT00809575
Quality of Life and Symptoms in Patients With Newly Diagnosed Myelodysplastic Syndromes No drug interventions Not Available Not Available unknown_status NCT00072475
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes treatment 2 completed NCT02721875
Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes treatment 1 terminated NCT04517175
Could Ki-67 be Used as a Diagnostic or Prognostic Marker in Hemato-oncological Diagnostics? No drug interventions Not Available Not Available not_yet_recruiting NCT00003675
Topotecan in Treating Patients With Myelodysplastic Syndrome treatment 2 completed NCT03699475
Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS treatment 2 / 3 terminated NCT04093570
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers treatment 2 enrolling_by_invitation NCT01409070
Head to Head Comparison of Azacitidine and Decitabine in Myelodysplastic Syndrome No drug interventions Not Available Not Available completed NCT00003270
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer treatment 2 completed NCT02631070
A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes treatment 3 completed NCT00186342
Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies No drug interventions treatment Not Available completed NCT04712942
Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat treatment 2 completed NCT00424242
Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases treatment 0 completed NCT00045942
PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2) treatment 1 / 2 completed NCT06566742
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia. treatment 2 not_yet_recruiting NCT03643042
Impact of 2 Transfusion Strategies on Quality of Life of Multitransfused Patients With Low-risk Myelodysplastic Syndrome No drug interventions prevention Not Available terminated NCT00569842
Investigation of the Cylex® ImmuKnow® Assay No drug interventions Not Available Not Available completed NCT05005299
Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation treatment 1 recruiting NCT00066599
Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy supportive_care 2 completed NCT00028899
Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes treatment 1 completed NCT00827099
Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer treatment 2 terminated NCT06508099
Vitamin A and D Supplementation in Allogeneic HCT treatment 2 recruiting NCT00071799
A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care other 3 completed NCT01302106
Study of Clofarabine in Combination With Low Dose Cytarabine to Treat Myelodysplastic Syndromes treatment 2 withdrawn NCT04151706
CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML treatment 2 completed NCT00453206
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases No drug interventions treatment Not Available completed NCT03074006
Dose Escalation and Proof-of-Concept Studies of Vactosertib (TEW-7197) Monotherapy in Patients With MDS treatment 1 completed NCT02240706
Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes treatment 2 terminated NCT00003406
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer treatment 1 / 2 completed NCT03176849
A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT No drug interventions treatment 4 completed NCT00085449
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer treatment 1 / 2 withdrawn NCT03733249
Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study treatment 1 / 2 terminated NCT06477549
BeFluBu vs FluBuRux Conditioning in Haploidentical HCT treatment 2 recruiting NCT06006949
Roxadustat Combined With Luspatercept Versus Luspatercept Monotherapy in the Treatment of Refractory MDS-RS treatment 4 not_yet_recruiting NCT00719849
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease treatment 2 terminated NCT00003336
Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions treatment 2 completed NCT00624936
Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes treatment 1 completed NCT04539236
Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients treatment 1 / 2 recruiting NCT00054236
Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia treatment 1 completed NCT00744536
Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS treatment 2 completed NCT05237713
Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients treatment 2 terminated NCT00253513
Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome treatment 1 / 2 completed NCT04764513
Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT No drug interventions treatment 1 / 2 recruiting NCT06046313
Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS treatment 2 recruiting NCT00898118
Studying Blood Samples in Young Patients With Cytopenia After a Donor Stem Cell Transplant No drug interventions Not Available Not Available unknown_status NCT00534118
Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant No drug interventions treatment Not Available completed NCT02008318
A Study of Galunisertib in Participants With Myelodysplastic Syndromes treatment 2 / 3 completed NCT00315419
Identifying Characteristics of Bone Marrow Failure Syndromes No drug interventions Not Available Not Available unknown_status NCT01386619
NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) treatment 1 / 2 completed NCT00016419
S0020 Immunosuppressive Therapy in Treating Patients With Myelodysplastic Syndrome treatment 2 completed NCT00770419
Perceptions of Burden in Patients With Late-Stage Cancer and Their Caregivers No drug interventions Not Available Not Available withdrawn NCT00290641
Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer treatment Not Available completed NCT00564941
Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload treatment 4 completed NCT02781441
Evaluation of a Question Prompt List for Patients With Myelodysplastic Syndromes (QPL-MDS) No drug interventions health_services_research Not Available unknown_status NCT04232241
Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia No drug interventions treatment 2 recruiting NCT00949117
Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer supportive_care 2 terminated NCT04167917
NTX-301 in MDS/AML No drug interventions treatment 1 recruiting NCT06247917
Evaluate the Efficacy and Safety of Allogeneic Haematopoietic Stem Cell Transplantation With FBM Conditioning for MDS treatment 2 recruiting NCT00002517
Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome treatment 3 completed NCT00043134
Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome treatment 3 unknown_status NCT00750334
A Study of Oral Clofarabine in Adult Patients With Myelodysplastic Syndromes (MDS) treatment 1 terminated NCT00049634
Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Disorder treatment 1 / 2 completed NCT05148234
BMS-986253 in Myelodysplastic Syndromes treatment 1 / 2 terminated NCT03904134
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702) No drug interventions treatment Not Available active_not_recruiting NCT04742634
Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant treatment 1 / 2 recruiting NCT00923234
Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes treatment 1 terminated NCT03483324
Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation No drug interventions treatment 1 completed NCT00823524
Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer treatment 1 / 2 completed NCT00027924
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Myelodysplastic Syndrome treatment 2 completed NCT00732316
Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematologic Cancer or Myelodysplastic Syndrome No drug interventions treatment 2 completed NCT00651716
T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant No drug interventions Not Available Not Available terminated NCT00003116
High-Dose Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer treatment 2 completed NCT00737516
Centralized Cord Blood Registry to Facilitate Unrelated Cord Blood Transplantation No drug interventions Not Available 2 completed NCT03533816
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide treatment 1 recruiting NCT03259516
Nivolumab With Chemotherapy in Refractory MDS treatment 1 / 2 terminated NCT00118196
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia treatment 2 terminated NCT00096096
Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation supportive_care 2 completed NCT00053196
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer treatment 2 completed NCT00547196
AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders treatment Not Available completed NCT00886496
Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia supportive_care 1 withdrawn NCT03169296
Clinical and Genomic Registry of MDS in Asia No drug interventions Not Available Not Available recruiting NCT06501196
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome No drug interventions treatment 1 recruiting NCT03810196
CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT No drug interventions treatment Not Available recruiting NCT00695396
A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion treatment 3 terminated NCT00618696
Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced Leukemia No drug interventions treatment 1 terminated NCT04095858
Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005) treatment 3 terminated NCT04361058
Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide treatment 1 withdrawn NCT02863458
DNA Hypomethylating Agents and Lenalidomide in Elderly Patients With Myeloid Malignancies in the US No drug interventions Not Available Not Available withdrawn NCT00004258
EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer treatment 1 completed NCT00003335
Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer treatment 2 completed NCT05365035
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts treatment 2 recruiting NCT04484363
Expanded Access Program With Pevonedistat (Given With Azacitidine) for Adults With Higher-risk Myelodysplastic Syndromes Not Available Not Available no_longer_available NCT02084563
Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms basic_science 2 completed NCT00005863
Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia treatment 3 completed NCT05968963
Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation No drug interventions supportive_care Not Available recruiting NCT00719563
American Ginseng in Treating Patients With Fatigue Caused by Cancer supportive_care 3 completed NCT00061763
Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias treatment 2 completed NCT00044486
Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899) prevention 3 completed NCT06047886
CD34 Selection Using the Automated CliniMACS Prodigy No drug interventions treatment 1 not_yet_recruiting NCT01129739
Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Myelodysplastic Syndromes No drug interventions treatment 2 unknown_status NCT00443339
Darbepoetin Alpha in Myelodysplastic Syndromes (MDS) treatment 2 unknown_status NCT02646839
KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children No drug interventions treatment 2 enrolling_by_invitation NCT01186939
An Extension to Study AZA PH GL 2003 CL 001 Allowing for Continuation of Azacitidine Treatment in Patients With Myelodysplastic Syndromes (MDS) treatment 3 completed NCT05275439
Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML treatment 1 recruiting NCT00006239
Phenylbutyrate and Tretinoin in Treating Patients With Hematologic Cancer treatment 1 completed NCT04582539
To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma No drug interventions treatment 1 / 2 completed NCT00001839
A Randomized Trial of Antithymocyte Globulin Versus Cyclosporine to Treat the Cytopenia of Myelodysplastic Syndrome treatment 2 completed NCT04798339
Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA treatment 1 / 2 recruiting NCT00005622
Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders treatment 2 completed NCT00042822
FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma treatment 2 completed NCT00086125
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED) treatment 2 completed NCT03377725
Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS) treatment 3 withdrawn NCT02228525
Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes treatment 2 completed NCT05617625
CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome treatment 2 suspended NCT00015925
MS-275 in Treating Patients With Hematologic Cancer treatment 1 completed NCT00023530
Blood and Marrow Transplant Clinical Research Network prevention Not Available completed NCT00534430
Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer treatment 2 active_not_recruiting NCT04771130
A Study of BGB-11417 in Participants With Myeloid Malignancies treatment 1 / 2 recruiting NCT00726830
Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer supportive_care Not Available terminated NCT03016130
Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101) No drug interventions supportive_care 3 terminated NCT00028730
Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer treatment 2 completed NCT00451048
Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia treatment 2 completed NCT05444348
Compassionate Communication and Advance Care Planning to Improve End of Life Care in Treatment of Hematological Disease (ACT) No drug interventions supportive_care Not Available recruiting NCT00066248
Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment supportive_care 2 completed NCT05350748
Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS No drug interventions Not Available Not Available recruiting NCT03066648
Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS treatment 1 completed NCT02900248
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice No drug interventions Not Available Not Available terminated NCT03238248
Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors treatment 2 active_not_recruiting NCT00003048
Amifostine in Treating Patients With Myelodysplastic Syndrome supportive_care 2 completed NCT04986657
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS No drug interventions diagnostic Not Available recruiting NCT00410657
Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant supportive_care 2 completed NCT00462657
Early Diagnosis of Aspergillosis in Patients at High Risk of Fungal Infection Caused by Treatment for Hematologic Cancer or Other Disease No drug interventions diagnostic Not Available unknown_status NCT03920657
Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS treatment 2 terminated NCT00114257
Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders treatment 1 completed NCT00053157
Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia supportive_care Not Available completed NCT01241357
High-Tc Susceptometer to Monitor Transfusional Iron Overload No drug interventions Not Available Not Available completed NCT00951626
A Standardized Nursing Intervention Protocol for HCT Patients No drug interventions health_services_research Not Available completed NCT00627666
Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer treatment 2 completed NCT00093366
Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes treatment 1 / 2 completed NCT04937166
A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies treatment 1 recruiting NCT00357565
Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia treatment 2 active_not_recruiting NCT02619565
Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes No drug interventions diagnostic Not Available completed NCT03233074
Constitution of a Biological Cohort Following Bone Marrow Sampling From MDS or AML Patients and Age-matched Healthy Donors No drug interventions Not Available Not Available terminated NCT05924074
Ferroptosis Study in SF3B1-mutant Myelodysplastic Syndromes (FerMDS) No drug interventions diagnostic Not Available not_yet_recruiting NCT00513474
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant supportive_care 1 completed NCT00334074
Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS treatment 2 completed NCT00274820
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder treatment 2 completed NCT06475820
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis treatment 2 / 3 active_not_recruiting NCT04217720
SNS-301 Monotherapy in High Risk MDS and CMML No drug interventions treatment 2 withdrawn NCT01810120
Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCT No drug interventions treatment 1 / 2 completed NCT00006220
Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy treatment 1 / 2 terminated NCT00392782
Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease treatment 2 terminated NCT03560882
A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies treatment 1 active_not_recruiting NCT00305682
Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant treatment 2 completed NCT04906031
Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations treatment 2 unknown_status NCT00003331
Combination Chemotherapy in Treating Patients With Advanced Cancer treatment 1 completed NCT04313231
Sterile Inflammation and Molecular Aberrations in MDS No drug interventions Not Available Not Available unknown_status NCT02996773
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine treatment 1 active_not_recruiting NCT03397173
TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid treatment 2 completed NCT00262873
Bortezomib in Treating Patients With Myelodysplastic Syndromes treatment 2 completed NCT02627573
Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT prevention 2 terminated NCT01088373
Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q treatment 2 completed NCT05362773
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies No drug interventions treatment 1 recruiting NCT06463327
ACHIEVE2 - Safety and Preliminary Efficacy of Intravenous TCB008 in Patients With Relapse or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)/AML treatment 1 not_yet_recruiting NCT00003827
Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome treatment 2 unknown_status NCT00054327
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer treatment 2 completed NCT01246076
Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents treatment 2 completed NCT00068276
Cholecalciferol in Treating Patients With Myelodysplastic Syndrome No drug interventions treatment 2 completed NCT00186576
Non-Myeloablative Allogeneic Transplant for Myelodysplastic Syndromes and Myeloproliferative Disorders No drug interventions treatment Not Available completed NCT06465160
A Study to Evaluate the MNV-201 in Patients With Low Risk MDS treatment 1 recruiting NCT00993694
Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone Not Available Not Available completed NCT05024994
A Study of E7820 in People With Bone Marrow (Myeloid) Cancers treatment 2 active_not_recruiting NCT04482894
Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS No drug interventions supportive_care 2 recruiting NCT05384691
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions treatment 2 recruiting NCT04477291
A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS treatment 1 active_not_recruiting NCT05063591
Removing Transfusion Dependence as a Barrier to Hospice Enrollment No drug interventions supportive_care Not Available active_not_recruiting NCT00551291
A Study of NeoRecormon (Epoetin Beta), CellCept (Mycophenolate Mofetil) and Prednisone in Patients With Low or Intermediate Myelodysplastic Syndromes. treatment 2 completed NCT00246662
Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies treatment 1 completed NCT00571662
Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant treatment 2 completed NCT00003662
Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases treatment 2 completed NCT03886662
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) treatment 1 / 2 recruiting NCT04797780
Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome treatment 3 recruiting NCT00503880
Clofarabine, Cytarabine, and G-CSF in Treating Patients With Myelodysplastic Syndromes treatment 1 / 2 terminated NCT00454480
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes treatment 2 / 3 completed NCT04973280
Study to Evaluate Additional Risk Minimisation Measures (aRMMs) for REBLOZYL Among Healthcare Professionals (HCPs) No drug interventions Not Available Not Available completed NCT00376480
Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant treatment 1 completed NCT00002980
Decitabine in Treating Patients With Melanoma or Other Advanced Cancer treatment 1 completed NCT03682029
Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid Malignancies No drug interventions prevention Not Available active_not_recruiting NCT02489929
Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by Azacytidine diagnostic Not Available unknown_status NCT01065129
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS) treatment 1 completed NCT02842229
A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic Neoplasms No drug interventions Not Available Not Available completed NCT04701229
Haploinsufficiency of the RBM22 and SLU7 Genes in Del(5q) Myelodysplastic Syndromes No drug interventions Not Available Not Available unknown_status NCT02201329
Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia treatment 1 completed NCT03884829
A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS No drug interventions treatment 1 unknown_status NCT04464889
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation No drug interventions treatment 1 withdrawn NCT06045689
A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants treatment 3 recruiting NCT00053989
NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders treatment 2 completed NCT00526292
Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant treatment 2 completed NCT05181592
Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome. treatment 3 recruiting NCT02269592
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome No drug interventions Not Available Not Available recruiting NCT03300492
Expanded Natural Killer Cells Following Haploidentical HSCT for AML/MDS No drug interventions treatment 1 / 2 recruiting NCT00005892
Study of Allogeneic Bone Marrow Transplantation Following Cyclophosphamide and Radiotherapy in Patients With Myelodysplastic Syndrome and Acute Leukemia Related to Fanconi's Anemia treatment Not Available completed NCT04055844
Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS treatment 2 completed NCT01892644
Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome treatment 2 withdrawn NCT03291444
CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS No drug interventions treatment 1 recruiting NCT00062140
Total-Body Irradiation, Cyclophosphamide, and Stem Cell Transplantation in Treating Patients With Hematologic Cancer treatment 1 completed NCT01077440
Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell Transplant No drug interventions Not Available Not Available terminated NCT00361140
Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) treatment 4 completed NCT00054340
Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder supportive_care 1 / 2 completed NCT00755040
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder prevention 3 completed NCT02841540
A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes treatment 1 terminated NCT00909467
Early Recognition of Pulmonary Arterial Hypertension in Myelodysplastic and Myeloproliferative Diseases No drug interventions Not Available Not Available completed NCT01417767
Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS treatment 2 / 3 unknown_status NCT04969367
Physical Activity in Transfusion Dependent Patients With Myelodysplastic Syndrome No drug interventions Not Available Not Available withdrawn NCT00005967
Tipifarnib in Treating Patients With Advanced Hematologic Cancer treatment 1 completed NCT00112567
Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer treatment 1 / 2 completed NCT00813501
Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases No drug interventions Not Available Not Available terminated NCT00352001
Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes treatment 1 / 2 completed NCT00448201
Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease treatment 2 completed NCT00053001
Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome supportive_care 2 completed NCT02576301
Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS treatment 1 / 2 unknown_status NCT04678401
IS-free Treg HaploHCT treatment 1 recruiting NCT05895201
High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD treatment 1 / 2 withdrawn NCT02497404
Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR treatment 2 completed NCT00004904
Stem Cell Transplantation in Treating Patients With Hematologic Cancer treatment 1 completed NCT00986804
Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant treatment 1 completed NCT03434704
Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole treatment 2 completed NCT04980404
Inqovi Maintenance Therapy in Myeloid Neoplasms treatment 1 recruiting NCT00963872
Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer treatment 1 / 2 terminated NCT00003572
Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers treatment 2 completed NCT02782468
A Study of Pevonedistat in Adult East Asian Participants treatment 1 completed NCT00499668
Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer supportive_care Not Available withdrawn NCT00396968
AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDS No drug interventions treatment 1 / 2 withdrawn NCT03502668
Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS treatment 1 / 2 active_not_recruiting NCT05428969
A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies treatment 1 / 2 recruiting NCT01058369
Exjade-Early-Trial treatment 2 terminated NCT05175469
Flow Cytometric Analysis of Peripheral Blood Neutrophil Myeloperoxidase Expression for Ruling Out Myelodysplastic Syndromes: Protocol for a Diagnostic Accuracy Study No drug interventions Not Available Not Available recruiting NCT00683046
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies treatment 2 completed NCT00255346
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) treatment 2 completed NCT00005946
Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation treatment 1 completed NCT00002746
Interleukin-2 in Treating Patients With Myelodysplastic Syndrome treatment 1 completed NCT00854646
Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS) treatment 1 completed NCT03493646
Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486 treatment 2 completed NCT03735446
Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial treatment 1 terminated NCT00602446
Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant supportive_care 2 terminated NCT04581512
Study to Evaluate the Safety and Tolerability of EP0042 treatment 1 / 2 recruiting NCT01101412
Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies supportive_care 1 / 2 withdrawn NCT04953312
Calprotectin, a Biomarker of COVID-19 Severity (CALPRO) No drug interventions diagnostic Not Available not_yet_recruiting NCT00379912
Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes treatment 2 terminated NCT00036712
Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation No drug interventions supportive_care 2 unknown_status NCT05483010
Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS) treatment 2 recruiting NCT03573310
A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS No drug interventions treatment 1 active_not_recruiting NCT05473910
A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation No drug interventions treatment 1 recruiting NCT04849910
Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS treatment 1 / 2 recruiting NCT04313881
Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) treatment 3 terminated NCT03433781
A Phase Ib Study Evaluating the Safety and Tolerability of Vitamin C in Patients With Intermediate or High Risk Myelodysplastic Syndrome With TET2 Mutations treatment 1 / 2 completed NCT04620681
CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML No drug interventions treatment 1 / 2 active_not_recruiting NCT00899795
Evaluating Cell Damage in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Fanconi Anemia; in Patients Who Were Exposed to Alkylating Agents; and in Healthy Volunteers No drug interventions Not Available Not Available completed NCT06569095
Measurable Residual Disease Assessment of Cells With Leukemic Stem Cells Associated Phenotype in Patients With Myelodysplastic Syndrome: a Multi-center, Prospective Clinical Study No drug interventions Not Available Not Available not_yet_recruiting NCT04296214
Pharmacoeconomics in the Application of 5-azacitidine in the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia Not Available Not Available withdrawn NCT00423514
Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease treatment 1 / 2 completed NCT05766514
Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction treatment 2 not_yet_recruiting NCT05636514
Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS treatment 1 recruiting NCT02981914
Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation treatment 0 completed NCT03286114
Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab treatment 1 terminated NCT00281814
Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow Transplant No drug interventions Not Available Not Available completed NCT03555955
A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 treatment 1 completed NCT00720850
Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) treatment 2 terminated NCT04460950
Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid Neoplasms No drug interventions Not Available Not Available recruiting NCT02328950
A 5 Day Course of Fludarabine and Cytarabine Followed by Full Intensity Allogeneic Stem Cell Transplantation (FA5-Bucy) in Treating Patients With High-risk, Recurrent or Refractory Acute Leukemia and Advanced Myelodysplastic Syndrome Not Available Not Available unknown_status NCT00006350
Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer treatment 2 completed NCT00800150
Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment treatment 1 terminated NCT06175923
Role of BMP Pathway in MDS Progression Not Available Not Available not_yet_recruiting NCT02593123
Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis treatment 2 completed NCT00003123
Amifostine in Treating Patients With Advanced Myelodysplastic Syndrome treatment 2 unknown_status NCT02758223
Prophylactic Application of Donor-derived TCM After Allogeneic HSCT No drug interventions treatment 1 / 2 completed NCT00005823
Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome treatment 3 completed NCT05991908
Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies treatment 3 recruiting NCT00673608
Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload treatment 4 completed NCT04628338
IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation treatment 0 completed NCT00398138
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma treatment 1 completed NCT06279338
A Novel Conditioning Regimen for Myelodysplastic Syndrome With Moderate High IPSS-M Score treatment Not Available not_yet_recruiting NCT06469138
A Phase 1 Study to Investigate 14C-bemcentinib Following Single Oral Administration in Healthy Male Subjects treatment 1 completed NCT00070538
VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies treatment 1 completed NCT03932643
ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant treatment 1 active_not_recruiting NCT03718143
AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis treatment 2 terminated NCT00234143
Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS) treatment 2 / 3 unknown_status NCT02955043
Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery No drug interventions supportive_care Not Available completed NCT00997243
Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes treatment 2 terminated NCT02752243
CIK-Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After SCT. No drug interventions treatment 1 / 2 unknown_status NCT00050843
A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes treatment 3 completed NCT01137643
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer No drug interventions Not Available Not Available recruiting NCT04999943
Hypomemylating Agents Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome No drug interventions prevention 1 recruiting NCT00003243
Combination Chemotherapy Plus Infusion of White Blood Cells in Treating Patients With Hematologic Cancer treatment 1 completed NCT06304103
A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome No drug interventions treatment 2 not_yet_recruiting NCT00446303
A Phase II Study of Maintenance With Azacitidine in MDS Patients treatment 2 terminated NCT00000603
Cord Blood Stem Cell Transplantation Study (COBLT) No drug interventions treatment 2 completed NCT05732103
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes No drug interventions treatment 1 / 2 recruiting NCT00935090
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer No drug interventions diagnostic Not Available recruiting NCT00002790
Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow Transplant supportive_care 1 / 2 withdrawn NCT00003790
Detection of Residual Disease in Children Receiving Therapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome No drug interventions Not Available Not Available completed NCT00002890
Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia treatment 1 completed NCT03744390
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome treatment 2 active_not_recruiting NCT03836690
Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation No drug interventions treatment 1 unknown_status NCT00522990
Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias treatment 1 / 2 terminated NCT06109064
Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With Higher-risk MDS treatment 2 recruiting NCT03912064
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT treatment 1 active_not_recruiting NCT05236764
Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion No drug interventions treatment Not Available recruiting NCT00022321
Gemtuzumab in Treating Patients With Myelodysplastic Syndrome treatment 2 unknown_status NCT00964821
Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant No drug interventions Not Available Not Available completed NCT02921802
A Study of Special Use Results Surveillance of Revlimid 5mg Capsules No drug interventions Not Available Not Available completed NCT05218902
A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No drug interventions Not Available Not Available completed NCT01009502
Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome treatment 1 terminated NCT05168202
A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes treatment 1 active_not_recruiting NCT00589602
T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases No drug interventions treatment 2 terminated NCT04273802
CPX-351 in Higher Risk Myelodysplastic Syndromes No drug interventions treatment 1 / 2 completed NCT00828802
Lenalidomide and Decitabine in High Grade Myelodysplastic Syndromes treatment 1 completed NCT00446602
A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) treatment 2 withdrawn NCT00002502
Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome treatment 2 completed NCT01728402
Pathogenesis of Hematologic Malignancies No drug interventions Not Available Not Available enrolling_by_invitation NCT02641002
A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS) No drug interventions treatment 1 terminated NCT05246384
Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia No drug interventions treatment 1 / 2 withdrawn NCT05342584
Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS treatment 1 recruiting NCT05949684
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions treatment 3 recruiting NCT00293384
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant supportive_care Not Available completed NCT04935684
Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation treatment 2 recruiting NCT03659084
Study of the Outcome of Patients With Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Receiving Iron Chelation Therapy After Allogeneic Hematopoietic Stem Cell Transplantation Not Available Not Available unknown_status NCT00003984
Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome treatment 2 withdrawn NCT00255684
Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer treatment Not Available terminated NCT02720679
Investigation of the Genetics of Hematologic Diseases No drug interventions Not Available Not Available recruiting NCT03795779
CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies treatment 0 unknown_status NCT00782379
Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer treatment 2 completed NCT03915379
A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) No drug interventions treatment 1 completed NCT06130579
Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT No drug interventions treatment 2 recruiting NCT02916979
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG treatment 1 completed NCT05068401
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies treatment 1 not_yet_recruiting NCT04976699
CD24Fc for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005) treatment 3 active_not_recruiting NCT03826082
PRGN-3006 Adoptive Cellular Therapy Relapsed or Refractory CD33-Positive AML or High Risk MDS treatment 1 not_yet_recruiting NCT01326377
ON 01910.Na for Intermediate1-2, or High Risk Trisomy 8 Myelodysplastic Syndrome (MDS) treatment 2 completed NCT00066300
Allogeneic Peripheral Stem Cell Transplantation Followed By Donor Lymphocyte Infusions in Treating Patients With Hematologic Cancer treatment 2 active_not_recruiting NCT02172768
Pharmacokinetics of Micafungin Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease other 2 completed NCT02805946
Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections prevention 4 completed NCT04741945
Repurposing Metformin as a Leukemia-preventive Drug in CCUS and LR-MDS other 2 recruiting NCT00943293
Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies treatment 1 terminated NCT00943592
Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies treatment 1 / 2 completed NCT02158858
A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis treatment 1 / 2 active_not_recruiting NCT04429191
JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation treatment 1 unknown_status NCT02231853
Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections No drug interventions prevention 1 terminated NCT03198234
Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders No drug interventions treatment 1 terminated NCT02093429
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS) No drug interventions treatment 1 / 2 terminated NCT04212390
Personalized Medicine Program on Myelodysplastic Syndromes: Characterization of the Patient's Genome for Clinical Decision Making and Systematic Collection of Real World Data to Improve Quality of Health Care No drug interventions Not Available Not Available recruiting NCT00467961
Stem Cell Transplantation for Patients With Cancers of the Blood No drug interventions treatment 2 completed NCT01866839
Preventing Stem Cell Transplant Complications With a Blood Separator Machine No drug interventions treatment 1 / 2 completed NCT01174108
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells No drug interventions treatment 2 recruiting NCT06548230
A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) treatment 1 / 2 not_yet_recruiting NCT04478227
TPO-Mimetic Use in Children for Hematopoietic Failure treatment 0 completed NCT05168904
A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS) treatment 1 / 2 suspended NCT05674539
Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome treatment 3 recruiting NCT06545682
Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA) treatment 1 / 2 not_yet_recruiting NCT01342289
Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide treatment 1 completed NCT05048498
Pharmacokinetics, Tolerability and Safety of NEX-18a treatment 1 completed NCT01885897
IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT treatment 1 / 2 completed NCT00528983
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia treatment 1 completed NCT02775383
The National Myelodysplastic Syndromes (MDS) Study No drug interventions Not Available Not Available active_not_recruiting NCT01995578
Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse treatment 2 completed NCT04985656
A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes treatment 2 withdrawn NCT03593915
A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS treatment 1 / 2 terminated NCT01355913
Screening and Genetic Monitoring of Patients With Myelodysplastic Syndromes (MDS) Under Different Treatment Modalities by Cytogenetic Analyses of Circulating CD34+Cells No drug interventions Not Available Not Available completed NCT02333058
Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies treatment 2 completed NCT02550535
A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients No drug interventions treatment 1 / 2 completed NCT06398457
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies treatment 0 not_yet_recruiting NCT01613976
A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients treatment 1 completed NCT04064060
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials treatment 3 recruiting NCT01392989
Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders treatment 2 completed NCT04395092
Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM) No drug interventions treatment 2 withdrawn NCT01034592
Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia treatment 1 terminated NCT02779569
A Clinical Trial Evaluating the Efficacy of Ultra Low Dose of Decitabine in Myelodysplastic Syndromes (MDS) treatment Not Available unknown_status NCT04872595
A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant treatment 2 active_not_recruiting NCT06581055
A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes Not Available Not Available not_yet_recruiting NCT02942290
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS) treatment 1 active_not_recruiting NCT05884333
Cord Blood Transplant in Adults With Blood Cancers No drug interventions treatment 2 recruiting NCT03849651
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies treatment 2 active_not_recruiting NCT05092451
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances treatment 1 / 2 recruiting NCT06465953
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation treatment 3 not_yet_recruiting NCT04997811
Repurposed Drugs to Improve Haematological Responses in Myelodysplastic Syndromes treatment 2 recruiting NCT01660607
Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell No drug interventions treatment 1 / 2 completed NCT01135849
B-Receptor Signaling in Cardiomyopathy No drug interventions Not Available Not Available completed NCT04275518
A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. treatment 1 recruiting NCT00594230
LBH589 in Refractory Myelodysplastic Syndromes (MDS) treatment 2 terminated NCT01488565
A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), With Eltrombopag Support for Thrombocytopenia treatment 2 completed NCT02966782
A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS) treatment 1 completed NCT00600860
A Prospective, Multicentre European Registry for Newly Diagnosed Patients With Myelodysplastic Syndromes No drug interventions Not Available Not Available unknown_status NCT02099669
Red Blood Cell Transfusion Thresholds and QOL in MDS No drug interventions treatment Not Available unknown_status NCT02390414
The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) Study No drug interventions Not Available Not Available completed NCT01442714
Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS treatment 2 terminated NCT04326764
Panobinostat Maintenance After HSCT fo High-risk AML and MDS treatment 3 terminated NCT00048412
Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H treatment 1 / 2 completed NCT00542971
Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006) treatment 1 / 2 completed NCT03603964
Guadecitabine Extension Study treatment 2 terminated NCT03486353
A Study of FF-10501-01 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome treatment 2 withdrawn NCT02175277
Darbepoetin Alfa MDS Companion Protocol treatment 3 completed NCT01520805
Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome treatment 2 withdrawn NCT02433483
Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients treatment 2 terminated NCT04284228
Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT No drug interventions treatment 1 / 2 active_not_recruiting NCT00542828
Rabbit Anti-thymocyte Globulin in the Treatment of Patients With Low to Intermediate-1 Risk Myelodysplastic Syndrome treatment 2 terminated NCT03600909
A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia treatment 2 terminated NCT02626715
Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS treatment 2 completed NCT01338337
Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia treatment 2 completed NCT04878432
STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS treatment 2 active_not_recruiting NCT02648932
The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With Immediate Haploidentical Plus Unrelated Cord Donor Search Versus Matched Unrelated Donor Search For AML And High-Risk MDS Patients No drug interventions treatment 2 terminated NCT03613532
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN treatment 1 recruiting NCT00672152
A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation No drug interventions treatment 1 terminated NCT02905552
Myelodysplasic Syndromes and Risk Factors for Infection No drug interventions Not Available Not Available unknown_status NCT06294275
A Study of Single and Multiple Dose Administration of LP-001 in Healthy Subjects No drug interventions treatment 1 active_not_recruiting NCT00923442
Biology Studies of Hematologic Cancers No drug interventions Not Available Not Available enrolling_by_invitation NCT01758042
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders No drug interventions treatment Not Available recruiting NCT02730299
Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS treatment 3 active_not_recruiting NCT00682799
Serial Analysis of Chimerism in Patients With Refractory Cytopenia (RC) Transplanted With Reduced Intensity Conditioning (RIC) No drug interventions Not Available Not Available completed NCT01362036
Phase I Study Evaluating TXA127 in Low/Intermediate-1 Risk Myelodysplastic Syndrome and Thrombocytopenia treatment 1 terminated NCT00145613
Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies No drug interventions treatment 2 completed NCT06550713
A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies treatment 1 recruiting NCT00656617
Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) treatment 2 completed NCT04639024
ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN treatment 2 terminated NCT00533416
Safety of ON 01910.Na in Patients With Myelodysplasia treatment 1 completed NCT00339196
5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS treatment 2 completed NCT01517035
Improving Blood Stem Cell Collection and Transplant Procedures No drug interventions treatment 1 / 2 completed NCT04912063
Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome treatment 1 terminated NCT01422486
Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome treatment 2 terminated NCT02238925
An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients No drug interventions treatment 2 completed NCT01599325
Study of Azacitidine to Evaluate Safety and Effectiveness for Chinese Patients With Higher Risk Myelodysplastic Syndrome treatment 2 completed NCT05665530
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies treatment 1 recruiting NCT01816230
Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM treatment 1 / 2 completed NCT02143830
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy treatment 2 recruiting NCT02259348
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation treatment 2 terminated NCT04812548
A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants treatment 2 terminated NCT01221857
Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies treatment 1 / 2 completed NCT02979366
Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome treatment 1 completed NCT05534620
Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics other 1 recruiting NCT02204020
Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS treatment 2 withdrawn NCT00280631
Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS) treatment 1 / 2 completed NCT05817331
Refine and Assess the Readability of Patient, Carer, and Clinician Treatment Preference in Myelodysplasia Questionnaire No drug interventions Not Available Not Available completed NCT03957876
CPX-351 Therapy for MDS After Hypomethylating Agent Failure treatment 2 terminated NCT02992860
Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY treatment 2 terminated NCT03516591
A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes treatment 1 completed NCT01211691
Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF) No drug interventions treatment 1 / 2 suspended NCT02200380
A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs treatment 2 terminated NCT00488592
Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers treatment 2 completed NCT02989844
Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT treatment 2 completed NCT02793544
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide treatment 2 completed NCT00749372
MRI Screening for Patients With Myelodysplastic Syndrome (MDS), Who Have Received Multiple Red Blood Cell Transfusions No drug interventions screening Not Available completed NCT00796068
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant treatment 2 completed NCT01842646
Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS) treatment 2 completed NCT04608110
A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome No drug interventions treatment 1 recruiting NCT02944955
A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) treatment 2 not_yet_recruiting NCT01286038
Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia treatment 1 terminated NCT03335943
Myelodysplastic Syndrome--CDA-2 Hematological Improvement National Affirmation Study No drug interventions treatment 4 unknown_status NCT02537990
MDS-CAN: A Prospective National MDS Clinical Database and Local Tissue Bank No drug interventions Not Available Not Available unknown_status NCT01050764
Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells treatment 1 / 2 terminated NCT01772953
Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT treatment 2 completed NCT00664677
Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia treatment 1 terminated NCT00666497
Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) treatment 2 terminated NCT02212561
Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome treatment 1 completed NCT01983761
Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation treatment 1 / 2 unknown_status NCT02790515
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation treatment 2 recruiting NCT02240537
Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer treatment 1 unknown_status NCT03173937
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome treatment 1 / 2 recruiting NCT00270452
Safety of Peptide Vaccination for Patients With Myelodysplastic Syndrome No drug interventions treatment 1 completed NCT02061800
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant treatment 1 / 2 active_not_recruiting NCT01459159
Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome treatment 2 terminated NCT00700206
Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS) treatment 2 completed NCT01685619
AML-MDS Novel Prognostic Tests Clinical Study No drug interventions Not Available Not Available completed NCT02920541
Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome treatment 1 completed NCT01224496
Traditional Chinese Medicine in the Supportive Management of Anaemic and Cytopenic (Leukopenia, Thrombocytopenia) Haematological Disorders No drug interventions supportive_care 1 / 2 completed NCT00566696
Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies treatment 2 completed NCT05143996
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) No drug interventions treatment 1 recruiting NCT04401748
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome treatment 3 active_not_recruiting NCT01034657
LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS) treatment 2 terminated NCT02099266
Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment No drug interventions treatment Not Available completed NCT02147873
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL treatment 2 terminated NCT00225992
Phase II Research Study of Arsenic Trioxide (Trisenox) in Patients With Myelodysplastic Syndrome (MDS) Not Available 2 terminated NCT04603001
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations treatment 1 active_not_recruiting NCT01413568
Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies No drug interventions treatment 1 / 2 completed NCT00502112
A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS) treatment 1 completed NCT00923910
Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood treatment 1 / 2 completed NCT00655395
Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine treatment 1 / 2 terminated NCT00673114
Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies No drug interventions treatment 1 / 2 completed NCT00186823
Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies No drug interventions treatment 3 completed NCT02749708
Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome No drug interventions treatment 1 terminated NCT01929408
Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients No drug interventions Not Available Not Available completed NCT02269579
Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment No drug interventions treatment 2 withdrawn NCT01861093
Safety Study of Cord Blood Units for Stem Cell Transplants No drug interventions treatment 2 recruiting NCT01553461
Transplants With Unlicensed Preserved Cord Blood No drug interventions treatment 1 / 2 recruiting NCT00977132
Efficacy and Tolerability of the Combination of Valproic Acid and Lenalidomide in the Treatment of Patients With Myelodysplastic Syndrome treatment 2 terminated NCT02124174
Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS treatment 2 unknown_status NCT01629082
Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia treatment 1 completed NCT03072498
Collection of Samples From Patients With MDS No drug interventions Not Available Not Available unknown_status NCT05709093
A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS) treatment 3 recruiting NCT04202003
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) treatment 1 / 2 completed